CA2661573A1 - Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic - Google Patents
Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic Download PDFInfo
- Publication number
- CA2661573A1 CA2661573A1 CA002661573A CA2661573A CA2661573A1 CA 2661573 A1 CA2661573 A1 CA 2661573A1 CA 002661573 A CA002661573 A CA 002661573A CA 2661573 A CA2661573 A CA 2661573A CA 2661573 A1 CA2661573 A1 CA 2661573A1
- Authority
- CA
- Canada
- Prior art keywords
- extended release
- dosage form
- tablet
- temperature
- polyethylene oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/005—Coating of tablets or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B7/00—Mixing; Kneading
- B29B7/02—Mixing; Kneading non-continuous, with mechanical mixing or kneading devices, i.e. batch type
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B7/00—Mixing; Kneading
- B29B7/80—Component parts, details or accessories; Auxiliary operations
- B29B7/88—Adding charges, i.e. additives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
- B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
- B29C35/04—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam
- B29C35/045—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
- B29C35/16—Cooling
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C37/00—Component parts, details, accessories or auxiliary operations, not covered by group B29C33/00 or B29C35/00
- B29C37/0025—Applying surface layers, e.g. coatings, decorative layers, printed layers, to articles during shaping, e.g. in-mould printing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
- B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
- B29C43/02—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor of articles of definite length, i.e. discrete articles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
- B29C43/32—Component parts, details or accessories; Auxiliary operations
- B29C43/52—Heating or cooling
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C71/00—After-treatment of articles without altering their shape; Apparatus therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C71/00—After-treatment of articles without altering their shape; Apparatus therefor
- B29C71/009—After-treatment of articles without altering their shape; Apparatus therefor using gases without chemical reaction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
- B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
- B29C35/04—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam
- B29C35/045—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames
- B29C2035/046—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames dried air
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
- B29C35/16—Cooling
- B29C2035/1658—Cooling using gas
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2071/00—Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
- B29K2071/02—Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0035—Medical or pharmaceutical agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/25—Solid
- B29K2105/251—Particles, powder or granules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
- B29K2995/0037—Other properties
- B29K2995/0088—Molecular weight
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/753—Medical equipment; Accessories therefor
Abstract
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and proces ses of manufacture, uses, and methods of treatment thereof.
Claims (164)
1. A process of preparing a solid oral extended release pharmaceutical dosage form, comprising at least the steps of:
(a) combining at least (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, and (2) at least one active agent, to form a composition;
(b) shaping the composition to form an extended release matrix formulation; and (c) curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 1 minute.
(a) combining at least (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, and (2) at least one active agent, to form a composition;
(b) shaping the composition to form an extended release matrix formulation; and (c) curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 1 minute.
2. The process of claim 1, wherein in step c) the extended release matrix formulation is subjected to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 5 minutes.
3. The process of claim 1, wherein in step c) the extended release matrix formulation is subjected to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 15 minutes.
4. The process of claim 1, 2 or 3, wherein in step b) the composition is shaped to form an extended release matrix formulation in the form of tablet.
5. The process of claim 4, wherein in step b) the composition is shaped by direct compression of said composition.
6. The process of any one of claims 1 to 5, wherein in step c) the extended release matrix formulation is subjected to a temperature of at least about 60 °C or at least about 62 °C, preferably at least about 68 °C, at least about 70 °C, at least about 72 °C or at least about 75 °C.
7. The process of claim 6, wherein the extended release matrix formulation is subjected to a temperature of from about 62 °C to about 90 °C, from about 65 °C to about 90 °C or from about 68 °C to about 90 °C.
8. The process of claim 6, wherein the extended release matrix formulation is subjected to a temperature of at least about 62 °C or at least about 68 °C for a time period of from about 1 minute to about 5 hours or from about 5 minutes to about 3 hours.
9. The process of claim 6, wherein the extended release matrix formulation is subjected to a temperature of at least about 62 °C or at least about 68 °C for a time period of at least about 15 minutes.
10. The process of claim 6, wherein the dosage form is subjected to a temperature of at least about 60 °C or at least about 62 °C, preferably at least about 68 °C, at least about 70 °C, at least about 72 °C or at least about 75 °C
or from about 62 °C to about 85 °C for a time period of at least about 15 minutes, at least about 30 minutes, at least about 60 minutes or at least about 90 minutes.
or from about 62 °C to about 85 °C for a time period of at least about 15 minutes, at least about 30 minutes, at least about 60 minutes or at least about 90 minutes.
11. The process of any one of claims 1 to 10, wherein the extended release matrix formulation in step c) is subjected to a temperature of at least about 60 °C or at least about 62 °C, but less than about 90 °C or less than about 80 °C.
12. The process of any one of claims 1 to 11, wherein the curing step c) takes place in an oven with an inside temperature.
13. The process of claim 12, wherein the temperature of step c) is the target inside temperature of the oven and wherein the curing step starts when the inside temperature of the oven reaches said temperature, and the curing step ends either when the heating is stopped or at least reduced and the inside temperature of the oven subsequently drops below said temperature by more than about 10 °C or below about 62 °C, in a plateau-like temperature profile or when the inside temperature of the oven drops below said temperature in a parabolic or triangular temperature profile.
14. The process of claim 13, wherein the temperature profile during the curing step shows a plateau-like form and wherein said temperature is preferably at least about 68 °C and the curing time is preferably in the range of from about 30 minutes to about 20 hours.
15. The process of any one of claims I to 11, wherein the curing step c) takes place in a convection curing device comprising an inlet air temperature, an exhaust air temperature and/or a temperature probe.
16. The process of claim 15, wherein the temperature of step c) is defined to be the target inlet air temperature and wherein the curing step starts when the inlet air temperature reaches said temperature and the curing step ends either when the heating is stopped or at least reduced and the inlet air temperature subsequently drops below said temperature by more than about 10 °C or below about 62 °C, in a plateau-like temperature profile or when the inlet air temperature drops below said temperature in a parabolic or triangular temperature profile.
17. The process of claim 16, wherein the temperature profile during the curing step shows a plateau-like form and wherein said temperature is preferably at least about 72 °C and the curing time is preferably in the range of from about 15 minutes to about 2 hours.
18. The process of claim 15, wherein the temperature of step c) is the target exhaust air temperature and wherein the curing step starts when the exhaust air temperature reaches said temperature and the curing step ends either when the heating is stopped or at least reduced and the exhaust air temperature subsequently drops below said temperature by more than about 10 °C or below about 62 °C, in a plateau-like temperature profile or when the exhaust air temperature drops below said temperature in a parabolic or triangular temperature profile.
19. The process of claim 18, wherein the temperature profile during the curing step shows a plateau-like form and wherein said temperature is preferably at least about 68 °C and the curing time is preferably in the range of from about 1 minute to about 2 hours.
20. The process of claim 15, wherein the temperature of step c) is the target temperature of the extended release matrix formulations and wherein the curing step starts when the temperature of the extended release matrix formulations reaches said temperature and the curing step ends either when the heating is stopped or at least reduced and the temperature of the extended release matrix formulations subsequently drops below said temperature by more than about 10 °C or below about 62 °C, in a plateau-like temperature profile or when the temperature of the extended release matrix formulations drops below said temperature in a parabolic or triangular temperature profile.
21. The process of claim 15, wherein the temperature of step c) is the target temperature measured using a temperature probe and wherein the curing step starts when the temperature measured using the temperature probe reaches said temperature and the curing step ends either when the heating is stopped or at least reduced and the temperature measured using the temperature probe subsequently drops below said temperature by more than about 10 °C or below about 62 °C, in a plateau-like temperature profile or when the temperature measured using the temperature probe drops below said temperature in a parabolic or triangular temperature profile.
22. The process of claim 21, wherein the temperature profile during the curing step shows a plateau-like form and wherein said temperature is preferably at least about 68°C and the curing time is preferably in the range of from about 15 minutes to about 2 hours.
23. The process of any one of claims 1 to 11 and 15 to 22, wherein the curing step c) takes place in a bed of free flowing extended release matrix formulations.
24. The process of claim 23, wherein the curing takes place in a coating pan.
25. The process of any one of claims 1 to 24, comprising a further step of coating the cured extended release matrix formulation.
26. The process of claim 25, comprising the steps of:
(a) combining at least (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, and (2) at least one active agent, to form a composition;
(b) shaping said composition to form the extended release matrix formulation in the form of a tablet by direct compression;
(c) curing said tablet by - subjecting a bed of free flowing tablets to a temperature from about 62°C to about 90°C for a time period of at least about 1 minute in a coating pan and - subsequently cooling the bed of free flowing tablets to a temperature of below about 50 °C;
and subsequently (d) coating the dosage form in said coating pan.
(a) combining at least (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, and (2) at least one active agent, to form a composition;
(b) shaping said composition to form the extended release matrix formulation in the form of a tablet by direct compression;
(c) curing said tablet by - subjecting a bed of free flowing tablets to a temperature from about 62°C to about 90°C for a time period of at least about 1 minute in a coating pan and - subsequently cooling the bed of free flowing tablets to a temperature of below about 50 °C;
and subsequently (d) coating the dosage form in said coating pan.
27. A process of preparing a solid oral extended release pharmaceutical dosage form, comprising at least the steps of:
(a) combining at least (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, and (2) at least one active agent, to form a composition;
(b) shaping the composition to form an extended release matrix formulation; and (c) curing said extended release matrix formulation comprising at least a curing step wherein said polyethylene oxide at least partially melts.
(a) combining at least (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000, and (2) at least one active agent, to form a composition;
(b) shaping the composition to form an extended release matrix formulation; and (c) curing said extended release matrix formulation comprising at least a curing step wherein said polyethylene oxide at least partially melts.
28. The process of claim 27, wherein in step b) the composition is shaped to form an extended release matrix formulation in the form of tablet.
29. The process of claim 28, wherein in step b) the composition is shaped by direct compression of said composition.
30. The process of claim 29, wherein at least about 20%, at least about 40% or at least about 75% of the high molecular weight polyethylene oxide melts.
31. The process of claim 30, wherein about 100% of the high molecular weight polyethylene oxide melts.
32. The process of any one of claims 27 to 31, wherein the curing step c) takes place in an oven.
33. The process of any one of claims 27 to 31, wherein the curing step c) takes place in a convection curing device.
34. The process of any one of claims 27 to 31, wherein the curing step c) takes place in a bed of free flowing extended release matrix formulations.
35. The process of claim 34, wherein the curing takes place in a coating pan.
36. The process of any one of claims 27 to 35, comprising a further step of coating the cured extended release matrix formulation.
37. The process of any one of claims 1 to 36, wherein the active agent is an opioid analgesic.
38. The process of claim 37 wherein the opioid analgesic is selected from the group of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing.
39. The process of claim 37, wherein the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing.
40. The process of claim 39, wherein the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from about 5 mg to about 500 mg of oxycodone hydrochloride.
41. The process of claim 40, wherein the dosage form comprises 5 mg, 7.5 mg, 10mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120mgor 160 mg of oxycodone hydrochloride.
42. The process of any one of claims 39 to 41, wherein the active agent is oxycodone hydrochloride and the oxycodone hydrochloride has a 14-hydroxycodeinone level of less than about 25 ppm, preferably of less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm.
43. The process of claim 37, wherein the opioid analgesic is oxymorphone hydrochloride and the dosage form comprises from about 1 mg to about 500 mg of oxymorphone hydrochloride.
44. The process of claim 43, wherein the dosage form comprises 5 mg, 7.5 mg, mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg or 160 mg of oxymorphone hydrochloride.
45. The process of claim 37, wherein the opioid analgesic is hydromorphone hydrochloride and the dosage form comprises from about 1 mg to about 100 mg of hydromorphone hydrochloride.
46. The process of claim 45, wherein the dosage form comprises 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg or 64 mg of hydromorphone hydrochloride.
47. The process of any one of claims 1 to 46, wherein the at least one polyethylene oxide has, based on rheological measurements, an approximate molecular weight of from 2,000,000 to 8,000,000.
48. The process of claim 47, wherein the at least one polyethylene oxide has, based on rheological measurements, an approximate molecular weight of 2,000,000, 4,000,000, 7,000,000 or 8,000,000.
49. The process of any one of claims 1 to 48, wherein the composition further comprises at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000.
50. The process of claim 49, wherein the composition further comprises at least one polyethylene oxide having, based on rheological measurements, an approximate - molecular weight of from 100,000 to 900,000.
51. The process of claim 50, wherein the composition further comprises at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 100,000.
52. The process of any one of claims 1 to 51, wherein the overall content of polyethylene oxide in the composition is at least about 80 % (by wt).
53. The process of any one of claims 1 to 52, wherein the active agent is oxycodone hydrochloride and the overall content of oxycodone hydrochloridein the composition is more than about 5% (by wt)
54. The process of any one of claims 1 to 53, wherein the content in the composition of the at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000 is at least about 80 % (by wt).
55. The process of any one of claims 1 to 54, wherein the composition comprises at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000 and at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000, wherein the composition comprises at least about 10 %
(by wt) or at least about 20 % (by wt) of the polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000.
(by wt) or at least about 20 % (by wt) of the polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000.
56. The process of claim 55, wherein the dosage form is subjected to a temperature of less than about 80 °C or less than about 77 °C.
57. The process of any one of claims 1 to 56, wherein the curing step c) leads to a decrease in the density of the extended release matrix formulation.
58. The process of claim 57, wherein the density of the cured extended release matrix formulation in comparison to the density of the uncured extended release matrix formulation decreases by at least about 0.5%, preferably at least about 0.7%.
59. A solid oral extended release pharmaceutical dosage form obtainable by a process according to any one of claims 1 to 58.
60. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation comprising an active agent in the form of a tablet or multi particulates, wherein the tablet or the individual multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or of the individual multi particulate after the flattening which corresponds to no more than about 60 %
of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 0.5 hours of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate of a non-flattened reference tablet or reference multi particulates.
of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 0.5 hours of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate of a non-flattened reference tablet or reference multi particulates.
61. The solid oral extended release pharmaceutical dosage form of claim 60, wherein the tablet or the multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or the individual multi particulate after the flattening which corresponds to no more than about 50 %, or no more than about 40%, or no more than about 30%, or no more than about 20%, or no more than about 16% of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 0.5 hours of dissolution that deviates no more than about 20 % points or no more than about 15 % points from the corresponding in-vitro dissolution rate of a non-flattened reference tablet or reference multi particulates.
62. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation comprising an active agent in the form of a tablet or multi particulates, wherein the tablet or the individual multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or of the individual multi particulate after the flattening which corresponds to no more than about 60 %
of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates and the non-flattened reference tablet or reference multi particulates provide an in-vitro dissolution rate, which when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, is between 5 and 40% (by wt) active agent released after 0.5 hours.
of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates and the non-flattened reference tablet or reference multi particulates provide an in-vitro dissolution rate, which when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, is between 5 and 40% (by wt) active agent released after 0.5 hours.
63. The solid oral extended release pharmaceutical dosage form of claim 62, wherein the tablet or the multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or the individual multi particulate after the flattening which corresponds to no more than about 50 %, or no more than about 40%, or no more than about 30%, or no more than about 20%, or no more than about 16% of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates and the non-flattened reference tablet or reference multi particulates provide an in-vitro dissolution rate, which when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, is between 5 and 40% (by wt) active agent released after 0.5 hours or is between 5 and 30% (by wt) active agent released after 0.5 hours or is between 5 and 20% (by wt) active agent released after 0.5 hours or is between 10 and 18% (by wt) active agent released after 0.5 hours.
64. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation comprising an active agent in the form of a tablet or multi particulates, wherein the tablet or the individual multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or the individual multi particulate after the flattening which corresponds to no more than about 60% of the thickness of the tablet or the individual multi particulate before flattening, and wherein the flattened or non flattened tablet or the flattened or non flattened multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) comprising 40%
ethanol at 37° C, characterized by the percent amount of active agent released at 0.5 hours of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°
C without ethanol, using a flattened and non flattened reference tablet or flattened and non flattened reference multi particulates, respectively.
ethanol at 37° C, characterized by the percent amount of active agent released at 0.5 hours of dissolution that deviates no more than about 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°
C without ethanol, using a flattened and non flattened reference tablet or flattened and non flattened reference multi particulates, respectively.
65. The solid oral extended release pharmaceutical dosage form of claim 64, wherein the tablet or the multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or the individual multi particulate after the flattening which corresponds to no more than about 60%, or no more than about 50%, or no more than about 40%, or no more than about 30%, or no more than about 20%, or no more than about 16% of the thickness of the tablet or the individual multi particulate before flattening, and wherein the flattened or non flattened tablet or the individual multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) comprising 40% ethanol at 37° C, characterized by the percent amount of active agent released at 0.5 hours of dissolution that deviates no more than about 20 % points or no more than about 15 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C without ethanol, using a flattened and a non flattened reference tablet or reference multi particulates, respectively.
66. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation comprising an active agent in the form of a tablet or multi particulates, wherein the tablet or the individual multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or the individual multi particulate after the flattening which corresponds to no more than about 60%
of the thickness of the tablet or the individual multi particulate before flattening, and wherein the flattened or non flattened tablet or the flattened or non flattened multi particulates provide an in-vitro dissolution rate, which when measured in a USP
Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) comprising 40% or 0% ethanol at 37° C, is between 5 and 40% (by wt) active agent released after 0.5 hours.
of the thickness of the tablet or the individual multi particulate before flattening, and wherein the flattened or non flattened tablet or the flattened or non flattened multi particulates provide an in-vitro dissolution rate, which when measured in a USP
Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) comprising 40% or 0% ethanol at 37° C, is between 5 and 40% (by wt) active agent released after 0.5 hours.
67. The solid oral extended release pharmaceutical dosage form of claim 66, wherein the tablet or the multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or the individual multi particulate after the flattening which corresponds to no more than about 50%, or no more than about 40%, or no more than about 30%, or no more than about 20%, or no more than about 16% of the thickness of the tablet or the individual multi particulate before flattening, and wherein the flattened or non flattened tablet or the individual multi particulates provide an in-vitro dissolution rate, which when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) comprising 40% or 0% ethanol at 37° C, is between 5 and 40% (by wt) active agent released after 0.5 hours or is between 5 and 30% (by wt) active agent released after 0.5 hours or is between 5 and 20% (by wt) active agent released after 0.5 hours or is between 10 and 18% (by wt) active agent released after 0.5 hours.
68. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) at least one active agent selected from opioid analgesics; and wherein the composition comprises at least about 80 % (by wt) polyethylene oxide.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) at least one active agent selected from opioid analgesics; and wherein the composition comprises at least about 80 % (by wt) polyethylene oxide.
69. The solid oral extended release pharmaceutical dosage form of claim 68, wherein the opioid analgesic is oxycodone hydrochloride or hydromorphone hydrochloride and the composition comprises more than 5% (by wt) of the oxycodone hydrochloride or hydromorphone hydrochloride.
70. The solid oral extended release pharmaceutical dosage form of claim 68, wherein the composition comprises at least about 80 % (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000.
71. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 10 mg oxycodone hydrochloride; and wherein the composition comprises at least about 85 % (by wt) polyethylene oxide.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 10 mg oxycodone hydrochloride; and wherein the composition comprises at least about 85 % (by wt) polyethylene oxide.
72. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 15 mg or 20 mg oxycodone hydrochloride; and wherein the composition comprises at least about 80 % (by wt) polyethylene oxide.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 15 mg or 20 mg oxycodone hydrochloride; and wherein the composition comprises at least about 80 % (by wt) polyethylene oxide.
73. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 40 mg oxycodone hydrochloride; and wherein the composition comprises at least about 65 % (by wt) polyethylene oxide.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 40 mg oxycodone hydrochloride; and wherein the composition comprises at least about 65 % (by wt) polyethylene oxide.
74. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 60 mg or 80 mg oxycodone hydrochloride; and wherein the composition comprises at least about 60 % (by wt) polyethylene oxide.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 60 mg or 80 mg oxycodone hydrochloride; and wherein the composition comprises at least about 60 % (by wt) polyethylene oxide.
75. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 8 mg hydromorphone hydrochloride; and wherein the composition comprises at least about 94 % (by wt) polyethylene oxide.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 8 mg hydromorphone hydrochloride; and wherein the composition comprises at least about 94 % (by wt) polyethylene oxide.
76. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 12 mg hydromorphone hydrochloride; and wherein the composition comprises at least about 92 % (by wt) polyethylene oxide.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 12 mg hydromorphone hydrochloride; and wherein the composition comprises at least about 92 % (by wt) polyethylene oxide.
77. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 32 mg hydromorphone hydrochloride; and wherein the composition comprises at least about 90 % (by wt) polyethylene oxide.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) 32 mg hydromorphone hydrochloride; and wherein the composition comprises at least about 90 % (by wt) polyethylene oxide.
78. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprsing a composition comprising at least:
(1) at least one active agent selected from opioid analgesics;
(2) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (3) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000.
(1) at least one active agent selected from opioid analgesics;
(2) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (3) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000.
79. The solid oral extended release pharmaceutical dosage form of claim 78, wherein the composition comprises at least about 80 % (by wt) of polyethylene oxide.
80. The solid oral extended release pharmaceutical dosage form of claim 78, wherein the composition comprises at least:
1. 15 to 30 % (by wt) of polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000; and 65 to 80 % (by wt) polyethylene oxide having, based on rheological measurements, a molecular weight of less than 1,000,000; or 2. at least about 20% (by wt) or at least about 30 % (by wt) or at least about 50 % (by wt) of polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000.
1. 15 to 30 % (by wt) of polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000; and 65 to 80 % (by wt) polyethylene oxide having, based on rheological measurements, a molecular weight of less than 1,000,000; or 2. at least about 20% (by wt) or at least about 30 % (by wt) or at least about 50 % (by wt) of polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000.
81. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, a molecular weight of at least 800,000; and (2) at least one active agent selected from opioid analgesics; and wherein the composition comprises at least about 80 % (by wt) polyethylene oxide.
(1) at least one polyethylene oxide having, based on rheological measurements, a molecular weight of at least 800,000; and (2) at least one active agent selected from opioid analgesics; and wherein the composition comprises at least about 80 % (by wt) polyethylene oxide.
82. The solid oral extended release pharmaceutical dosage form of claim 81, wherein the composition comprises at least one polyethylene oxide having, based on rheological measurements, a molecular weight of at least 900,000.
83. The solid oral extended release pharmaceutical dosage form of anyone of claims 59 to 82, wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm, preferably equal to or less than about 1.19 g/cm3.
84. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) at least one active agent; and wherein the extended release matrix formulation when subjected to an indentation test has a cracking force of at least about 110 N.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) at least one active agent; and wherein the extended release matrix formulation when subjected to an indentation test has a cracking force of at least about 110 N.
85. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) at least one active agent; and wherein the extended release matrix formulation when subjected to an indentation test has a "penetration depth to crack distance" of at least about 1.0 mm.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) at least one active agent; and wherein the extended release matrix formulation when subjected to an indentation test has a "penetration depth to crack distance" of at least about 1.0 mm.
86. The solid oral extended release pharmaceutical dosage form of any one of claims 84 and 85, wherein the extended release matrix formulation has a cracking force of at least about 120 N, at least about 130 N or at least about 140 N and/or a "penetration depth to crack" distance of at least about 1.2 mm, preferably of at least about 1.4 mm, at least about 1.5 mm or at least about 1.6 mm.
87. The solid oral extended release pharmaceutical dosage form of any one of claims 84 and 85, wherein the extended release matrix formulation resists a work of at least about 0.06 J without cracking.
88. The solid oral extended release pharmaceutical dosage form of anyone of claims 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C
and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage.
and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage.
89. The solid oral extended release pharmaceutical dosage form of claim 88, wherein the extended release matrix formulation has been stored at 40 °C and 75 % relative humidity (RH).
90. The solid oral extended release pharmaceutical dosage form of anyone of claims 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C
and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10 %
points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage.
and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10 %
points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage.
91. The solid oral extended release pharmaceutical dosage form of claim 90, wherein the extended release matrix formulation has been stored at 40 °C and 75 %
relative humidity (RH).
relative humidity (RH).
92. The solid oral extended release pharmaceutical dosage form of anyone of claims 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the dosage provides a dissolution rate, which when measured in a USP
Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, is between 12.5 and 55% (by wt) active released after 1 hour, between 25 and 65% (by wt) active released after 2 hours, between 45 and 85%
(by wt) active released after 4 hours and between 55 and 95% (by wt) active released after 6 hours.
Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, is between 12.5 and 55% (by wt) active released after 1 hour, between 25 and 65% (by wt) active released after 2 hours, between 45 and 85%
(by wt) active released after 4 hours and between 55 and 95% (by wt) active released after 6 hours.
93. The solid oral extended release pharmaceutical dosage form of anyone of claims 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin.TM..
94. The solid oral extended release pharmaceutical dosage form of anyone of claims 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing:
a) Oxycodone hydrochloride: 10.0 mg/tablet b) Lactose (spray-dried): 69.25 mg/tablet c) Povidone : 5.0 mg/tablet d) Eudragit® RS 30D (solids) : 10.0 mg/tablet e) Triacetin®: 2.0 mg/tablet f) Stearyl alcohol: 25.0 mg/tablet g) Talc: 2.5 mg/tablet h) Magnesium Stearate: 1.25 mg/tablet;
and wherein the reference tablet is prepared by the following steps:
1. Eudragit® RS 30D and Triacetin® are combined while passing through a 60 mesh screen, and mixed under low shear for approximately 5 minutes or until a uniform dispersion is observed.
2. Oxycodone HCl, lactose, and povidone are placed into a fluid bed granulator/dryer (FBD) bowl, and the suspension sprayed onto the powder in the fluid bed.
3. After spraying, the granulation is passed through a #12 screen if necessary to reduce lumps.
4. The dry granulation is placed in a mixer.
5. In the meantime, the required amount of stearyl alcohol is melted at a temperature of approximately 70 °C.
6. The melted stearyl alcohol is incorporated into the granulation while mixing.
7. The waxed granulation is transferred to a fluid bed granulator/dryer or trays and allowed to cool to room temperature or below.
8. The cooled granulation is then passed through a #12 screen.
9. The waxed granulation is placed in a mixer/blender and lubricated with the required amounts of talc and magnesium stearate for approximately 3 minutes.
10. The granulate is compressed into 125 mg tablets on a suitable tableting machine.
a) Oxycodone hydrochloride: 10.0 mg/tablet b) Lactose (spray-dried): 69.25 mg/tablet c) Povidone : 5.0 mg/tablet d) Eudragit® RS 30D (solids) : 10.0 mg/tablet e) Triacetin®: 2.0 mg/tablet f) Stearyl alcohol: 25.0 mg/tablet g) Talc: 2.5 mg/tablet h) Magnesium Stearate: 1.25 mg/tablet;
and wherein the reference tablet is prepared by the following steps:
1. Eudragit® RS 30D and Triacetin® are combined while passing through a 60 mesh screen, and mixed under low shear for approximately 5 minutes or until a uniform dispersion is observed.
2. Oxycodone HCl, lactose, and povidone are placed into a fluid bed granulator/dryer (FBD) bowl, and the suspension sprayed onto the powder in the fluid bed.
3. After spraying, the granulation is passed through a #12 screen if necessary to reduce lumps.
4. The dry granulation is placed in a mixer.
5. In the meantime, the required amount of stearyl alcohol is melted at a temperature of approximately 70 °C.
6. The melted stearyl alcohol is incorporated into the granulation while mixing.
7. The waxed granulation is transferred to a fluid bed granulator/dryer or trays and allowed to cool to room temperature or below.
8. The cooled granulation is then passed through a #12 screen.
9. The waxed granulation is placed in a mixer/blender and lubricated with the required amounts of talc and magnesium stearate for approximately 3 minutes.
10. The granulate is compressed into 125 mg tablets on a suitable tableting machine.
95. The extended release dosage form of claims 84 to 94, wherein the composition comprises at least about 80 % (by wt) of polyethylene oxide.
96. The extended release dosage form of claim 95, wherein the composition comprises at least about 80 % (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000.
97. The extended release dosage form of any one of claims 60 to 96, wherein the active agent is an opioid analgesic.
98. The extended release dosage form of claim 97, wherein the opioid analgesic is selected from the group of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing.
99. The extended release dosage form of claim 97, wherein the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing.
100. The extended release dosage form of claim 98, wherein the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from about 5 mg to about 500 mg of oxycodone hydrochloride.
101. The extended release dosage form of claim 100, wherein the dosage form comprises 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 60 mg, or mg, 90 mg, 120 mg or 160 mg of oxycodone hydrochloride.
102. The extended release dosage form of claim 97, wherein the opioid analgesic is oxycodone hydrochloride having a 14-hydroxycodeinone level of less than about 25 ppm, preferably of less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm.
103. The extended release dosage form of claim 97, wherein the opioid analgesic is oxymorphone hydrochloride and the dosage form comprises from about 1 mg to about 500 mg of oxymorphone hydrochloride.
104. The extended release dosage form of claim 103, wherein the dosage form comprises 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg or 160 mg of oxymorphone hydrochloride.
105. The extended release dosage form of claim 97, wherein the opioid analgesic is hydromorphone hydrochloride and the dosage form comprises from about 1 mg to about 100 mg of hydromorphone hydrochloride.
106. The extended release dosage form of claim 105, wherein the dosage form comprises 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg or 64 mg of hydromorphone hydrochloride.
107. The extended release dosage form of any one of claims 60 to 106, which is in the form of a tablet formed by direct compression of the composition and cured by at least subjecting said tablet to a temperature of at least about 60 °C or at least about 62 °C for a time period of at least about 1 minute, preferably at least about 5 minutes or at least about 15 minutes.
108. The extended release dosage form of any one of claims 60 to 107, which is in the form of a tablet and which is over coated with a polyethylene oxide powder layer to form a tablet that has a core tablet and a layer of polyethylene oxide surrounding the core tablet.
109. The extended release dosage form of any one of claims 60 to 107, which is in the form of a stacked bi or multi layered tablet, wherein one of the layers contains an extended release formulation and one of the other layers contains an immediate release formulation.
110. The extended release dosage form of claim 109, wherein the extended release formulation and the immediate release formulation contain the same or different active agents.
111. The extended release dosage form of claim 109, wherein the extended release formulation comprises an opioid analgesic and the immediate release formulation comprises a non opioid analgesic.
112. A method of treatment wherein a dosage form according to any one of claims 60 to 111 is administered for treatment of pain to a patient in need thereof, wherein the dosage form comprises an opioid analgesic.
113. Use of a dosage form according to any one of claims 60 to 111 for the manufacture of a medicament for the treatment of pain, wherein the dosage form comprises an opioid analgesic.
114. Use of high molecular weight polyethylene oxide that has, based on rheological measurements, a molecular weight of at least 1,000,000, as matrix forming material in the manufacture of a solid extended release oral dosage form comprising an active agent selected from opioids for imparting to the solid extended release oral dosage form resistance to alcohol extraction.
115. A process of preparing a solid oral extended release pharmaceutical dosage form, comprising at least the steps of:
(a) combining at least (1) at least one polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000, and (2) at least one active agent, to form a composition;
(b) shaping the composition to form an extended release matrix formulation; and (c) curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least 5 minutes.
(a) combining at least (1) at least one polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000, and (2) at least one active agent, to form a composition;
(b) shaping the composition to form an extended release matrix formulation; and (c) curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least 5 minutes.
116. The process of claim 115, wherein the composition is shaped to form an extended release matrix formulation in the form of tablet.
117. The process of claim 116, wherein the composition is shaped by direct compression of said composition.
118. The process of any one of claims 115 to 117, wherein in step c) the extended release matrix formulation is subjected to a temperature of at least 60 °C.
119. The process of claim 118 wherein the extended release matrix formulation is subjected to a temperature of from 65 °C to 90 °C.
120. The process of claim 118, wherein the extended release matrix formulation is subjected to a temperature at of least 60 °C or form 65 °C to 90 °C for a time period of at least 15 minutes or at least 30 minutes.
121. The process of claim 118, wherein the dosage form is subjected to a temperature of at least 60 °C or from 65 °C to 85 °C for a time period of at least 60 minutes, at least 75 minutes, at least 90 minutes or for 120 minutes.
122. The process of any one of claims 115 to 121, wherein the extended release matrix formulation in step c) is subjected to a temperature of at least 60 °C, but less than 90 °C or less than 80 °C.
123. The process of any one of claims 115 to 122, wherein the curing step c) takes place in an oven.
124. The process of any one of claims 115 to 122, wherein the curing step c) takes place in a bed of free flowing extended release matrix formulations.
125. The process of claim 124, wherein the curing takes place in a coating pan.
126. The process of any one of claims 115 to 125, comprising a further step of coating the cured extended release matrix formulation.
127. The process of claim 126, comprising the steps of:
(a) combining at least (1) at least one polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000, and (2) at least one active agent, to form a composition;
(b) shaping said composition to form the extended release matrix formulation in the form of a tablet by direct compression;
(c) curing said tablet by - subjecting a bed of free following tablets to a temperature from 70°C
to 90°C for a time period of at least 30 minutes in a coating pan and - subsequently cooling the bed of free flowing tablets to a temperature of below 50 °C;
and subsequently (d) coating the dosage form in said coating pan.
(a) combining at least (1) at least one polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000, and (2) at least one active agent, to form a composition;
(b) shaping said composition to form the extended release matrix formulation in the form of a tablet by direct compression;
(c) curing said tablet by - subjecting a bed of free following tablets to a temperature from 70°C
to 90°C for a time period of at least 30 minutes in a coating pan and - subsequently cooling the bed of free flowing tablets to a temperature of below 50 °C;
and subsequently (d) coating the dosage form in said coating pan.
128. The process of any one of claims 115 to 127, wherein the active agent is an opioid analgesic.
129. The process of claim 128 wherein the opioid analgesic is selected from the group of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl and derivatives, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing.
130. The process of claim 128, wherein the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing.
131. The process of claim 128, wherein the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from 5 mg to 500 mg of oxycodone hydrochloride.
132. The process of claim 131 wherein the dosage form comprises 5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg or 160 mg oxycodone hydrochloride.
133. The process of claim 128, wherein the opioid analgesic is oxymorphone hydrochloride and the dosage form comprises from 1 mg to 500 mg of oxymorphone hydrochloride.
134. The process of claim 133 wherein the dosage form comprises 5 mg, 10 mg, 15 mg, 20 mg, 30, mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg or 160 mg oxymorphone hydrochloride.
135. The process of claim 128, wherein the opioid analgesic is hydromorphone hydrochloride and the dosage form comprises from 1 mg to 100 mg of hydromorphone hydrochloride.
136. The process of claim 135, wherein the dosage form comprises 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg or 64 mg hydromorphone hydrochloride.
137. The process of any one of claims 115 to 136, wherein the at least one polyethylene oxide has, based on rheological measurements, an approximate molecular weight of from 2,000,000 to 8,000,000.
138. The process of claim 136, wherein the at least one polyethylene oxide has, based on rheological measurements, an approximate molecular weight of 2,000,000, 4,000,000, 7,000,000 or 8,000,000.
139. The process of any one of claims 115 to 138, wherein the composition further comprises at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000.
140. The process of claim 139, wherein the composition further comprises at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of from 100,000 to 900,000.
141. The process of claim 139, wherein the composition further comprises at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 100,000.
142. The process of any one of claims 115 to 141, wherein the overall content of polyethylene oxide in the composition is at least 80 % (by wt).
143. The process of any one of claims 115 to 142, wherein the content in the composition of the at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000 is at least 80 % (by wt).
144. The process of any one of claims 115 to 143, wherein the composition comprises at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000 and at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000, wherein the composition comprises at least % (by wt) or at least 20 % (by wt) of the polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000.
145. The process of claim 144, wherein the dosage form is subjected to a temperature of less than 80 °C or less than 77 °C.
146. A solid oral extended release pharmaceutical dosage form obtainable by a process according to any one of claims 115 to 145.
147. A solid oral extended release pharmaceutical dosage form comprising a extended release matrix formulation in the form of a tablet or multi particulates, wherein the tablet or the individual multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or of the individual multi particulate after the flattening which corresponds to no more than 60 % of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the flattened multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active released at 0.5 hours of dissolution that deviates no more than 20 %
points from the corresponding in-vitro dissolution rate of a non-flattened reference tablet or reference multi particulates.
points from the corresponding in-vitro dissolution rate of a non-flattened reference tablet or reference multi particulates.
148. The solid oral extended release pharmaceutical dosage form of claim 147, wherein the tablet or the multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or the individual multi particulate after the flattening which corresponds to no more than 50 %, or no more than 40%, or no more than 30%, or no more than 20%, or no more than 16% of the thickness of the tablet or the individual multi particulate before flattening, and wherein said flattened tablet or the multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active released at 0.5 hours of dissolution that deviates no more than 20 % points or no more than 15 %
points from the corresponding in-vitro dissolution rate of a non-flattened reference tablet or reference multi particulates.
points from the corresponding in-vitro dissolution rate of a non-flattened reference tablet or reference multi particulates.
149. A solid oral extended release pharmaceutical dosage form comprising a extended release matrix formulation in the form of a tablet or multi particulates, wherein the tablet or the individual multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or the individual multi particulate after the flattening which corresponds to no more than 60% of the thickness of the tablet or the individual multi particulate before flattening, and wherein the flattened or non flattened tablet or the flattened or non flattened multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) comprising 40% ethanol at 37° C, characterized by the percent amount of active released at 0.5 hours of dissolution that deviates no more than 20 % points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C without ethanol, using a flattened and non flattened reference tablet or flattened and non flattened reference multi particulates, respectively.
150. The solid oral extended release pharmaceutical dosage form of claim 149, wherein the tablet or the multi particulates can at least be flattened without breaking, characterized by a thickness of the tablet or the individual multi particulate after the flattening which corresponds to no more than 60%, or no more than 50%, or no more than 40%, or no more than 30%, or no more than 20%, or no more than 16% of the thickness of the tablet or the individual multi particulate before flattening, and wherein the flattened or non flattened tablet or the individual multi particulates provide an in-vitro dissolution rate, when measured in a USP Apparatus 1(basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) comprising 40%
ethanol at 37° C, characterized by the percent amount of active released at 0.5 hours of dissolution that deviates no more than 20 % points or no more than 15 %
points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°
C without ethanol, using a flattened and a non flattened reference tablet or reference multi particulates, respectively.
ethanol at 37° C, characterized by the percent amount of active released at 0.5 hours of dissolution that deviates no more than 20 % points or no more than 15 %
points from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°
C without ethanol, using a flattened and a non flattened reference tablet or reference multi particulates, respectively.
151. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) at least one active agent; and wherein the composition comprises at least 80 % (by wt) polyethylene oxide.
(1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (2) at least one active agent; and wherein the composition comprises at least 80 % (by wt) polyethylene oxide.
152. The solid oral extended release pharmaceutical dosage form of claim 151, wherein the composition comprises at least 80 % (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000.
153. A solid oral extended release pharmaceutical dosage form comprising an extended release matrix formulation, the extended release matrix formulation comprising a composition comprising at least:
(1) at least one active agent;
(2) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (3) at least one polyethylene oxide having, based on rheological measurements, a molecular weight of less than 1,000,000.
(1) at least one active agent;
(2) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000;
and (3) at least one polyethylene oxide having, based on rheological measurements, a molecular weight of less than 1,000,000.
154. The extended release dosage form of claim 153, wherein the composition comprises at least 80 % (by wt) of polyethylene oxide.
155. The extended release dosage form of any one of claims 151 to 154, which is in the form of a tablet formed by direct compression of the composition and cured by at least subjecting said tablet to a temperature of the least 60 °C for a time period of at least 15 minutes.
156. The extended release dosage form of any one of claims 146 to 155, which is in the form of a tablet and which is over coated with a polyethylene oxide powder layer to form a tablet that has a core tablet and a layer of polyethylene oxide surrounding the core tablet.
157. The extended release dosage form of any one of claims 146 to 155, which is in the form of a stacked bi or multi layered tablet, wherein one of the layers contains an extended release formulation and one of the other layers contains an immediate release formulation.
158. The extended release dosage form of claim 157, wherein the extended release formulation and the immediate release formulation contain the same or different active agents.
159. The extended release dosage form of claim 157, wherein the extended release formulation comprises an opioid analgesic and the immediate release formulation comprises a non opioid analgesic..
160. A method of treatment wherein a dosage form according to any one of claims 146 to 155 is administered for treatment of pain to a patient in need thereof, wherein the dosage form comprises an opioid analgesic.
161. Use of a dosage form according to any one of claims 146 to 155 for the manufacture of a medicament for the treatment of pain, wherein the dosage form comprises an opioid analgesic.
162. Use of high molecular weight polyethylene oxide that has, based on rheological measurements, a molecular weight of at least 1,000,000, as matrix forming material in the manufacture of a solid extended release oral dosage form comprising an active selected from opioids for imparting to the solid extended release oral dosage form resistance to alcohol extraction.
163. The process of any one of claims 1 to 58 and 115 to 145, wherein the curing is conducted at atmospheric pressure.
164. The process of any one of claims 23, 24, 124 and 125, wherein magnesium stearate is added during or after the curing step.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2707204A CA2707204C (en) | 2006-08-25 | 2007-08-24 | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84024406P | 2006-08-25 | 2006-08-25 | |
US60/840,244 | 2006-08-25 | ||
PCT/IB2007/002515 WO2008023261A1 (en) | 2006-08-25 | 2007-08-24 | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2707204A Division CA2707204C (en) | 2006-08-25 | 2007-08-24 | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2661573A1 true CA2661573A1 (en) | 2008-02-28 |
CA2661573C CA2661573C (en) | 2010-10-26 |
Family
ID=38754532
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2661573A Active CA2661573C (en) | 2006-08-25 | 2007-08-24 | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
CA2707204A Active CA2707204C (en) | 2006-08-25 | 2007-08-24 | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2707204A Active CA2707204C (en) | 2006-08-25 | 2007-08-24 | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
Country Status (42)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114659554A (en) * | 2022-03-01 | 2022-06-24 | 安徽农业大学 | Fault diagnosis method for biomass granulator |
Families Citing this family (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
JP4865330B2 (en) | 2002-12-13 | 2012-02-01 | デュレクト コーポレーション | Oral drug delivery system |
ATE495732T1 (en) | 2003-03-26 | 2011-02-15 | Egalet As | CONTROLLED RELEASE MORPHINE SYSTEM |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
US20070048228A1 (en) * | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004020220A1 (en) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102004032103A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
PT2767292T (en) | 2004-09-17 | 2016-11-23 | Durect Corp | Sustained local anesthetic composition containing saib |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
AU2006254554B2 (en) * | 2005-06-03 | 2011-11-24 | Egalet Ltd | A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
SA07280459B1 (en) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
ES2388355T3 (en) | 2006-11-03 | 2012-10-11 | Durect Corporation | Transdemic delivery systems comprising bupivacaine |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
US20080318994A1 (en) * | 2007-06-21 | 2008-12-25 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment |
CN101801350A (en) | 2007-08-13 | 2010-08-11 | 阿巴斯迪特宁医药有限公司 | Abuse resistant drugs, using method and preparation method |
WO2009088414A2 (en) | 2007-12-06 | 2009-07-16 | Durect Corporation | Oral pharmaceutical dosage forms |
US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
EP2262484B1 (en) * | 2008-03-11 | 2013-01-23 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
HUE030803T2 (en) | 2008-05-09 | 2017-06-28 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
US20110165248A1 (en) * | 2008-09-18 | 2011-07-07 | Meridith Lee Machonis | Pharmaceutical dosage forms comprising poly(e-caprolactone) |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
ES2414856T3 (en) | 2008-12-12 | 2013-07-23 | Paladin Labs Inc. | Narcotic drug formulations with decreased addiction potential |
WO2010088911A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Pharmaceutical compositions resistant to abuse |
NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
US20100280059A1 (en) * | 2009-05-01 | 2010-11-04 | Atley Pharmaceuticals, Inc. | Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations |
JP2012525423A (en) * | 2009-05-01 | 2012-10-22 | アトリー ファーマシューティカルズ インコーポレイテッド | Composition comprising antihistamine, antitussive and decongestant in sustained release preparation |
NZ603579A (en) | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
RU2555531C2 (en) | 2009-07-22 | 2015-07-10 | Грюненталь Гмбх | Misuse protected dosage form for oxidation sensitive opioids |
KR101738369B1 (en) | 2009-07-22 | 2017-05-22 | 그뤼넨탈 게엠베하 | Hot-melt extruded controlled release dosage form |
WO2011026125A2 (en) * | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
EP3064064A1 (en) | 2009-09-30 | 2016-09-07 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9579285B2 (en) | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
EP2568965A1 (en) | 2010-05-10 | 2013-03-20 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
NZ700732A (en) | 2010-05-10 | 2015-08-28 | Euro Celtique Sa | Pharmaceutical compositions comprising hydromorphone and naloxone |
WO2011141489A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
AR081931A1 (en) | 2010-06-15 | 2012-10-31 | Gruenenthal Gmbh | PHARMACEUTICAL COMBINATION |
EP2611426B1 (en) | 2010-09-02 | 2014-06-25 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
AR082862A1 (en) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | ALTERATION RESISTANT DOSAGE FORM INCLUDING AN ANIONIC POLYMER |
AU2011342893A1 (en) | 2010-12-13 | 2013-05-02 | Purdue Pharma L.P. | Controlled release dosage forms |
CN104856966A (en) * | 2010-12-22 | 2015-08-26 | 普渡制药公司 | Coated tamper-resistant controlled release dosage form |
EP2826468A1 (en) * | 2010-12-22 | 2015-01-21 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
CN103327969A (en) | 2010-12-23 | 2013-09-25 | 普渡制药公司 | Tamper resistant solid oral dosage forms |
HUE026981T2 (en) * | 2011-03-25 | 2016-08-29 | Purdue Pharma Lp | Controlled release pharmaceutical dosage forms |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
AT511581A1 (en) | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | ORAL RETARDANT FORMULATION |
EA201400172A1 (en) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | SUSTAINABLE TO DESTRUCTION TABLET THAT PROVIDES IMMEDIATE RELEASE OF MEDICINES |
AR087359A1 (en) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | TEST ALTERATION TABLET PROVIDING IMMEDIATE RELEASE OF THE PHARMACO |
US20140341984A1 (en) * | 2011-09-16 | 2014-11-20 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
WO2013038268A1 (en) * | 2011-09-16 | 2013-03-21 | Purdue Pharma L.P. | Tamper resistant immediate release formulations |
MX356210B (en) * | 2011-10-18 | 2018-05-18 | Purdue Pharma Lp | Acrylic polymer formulations. |
EA201400590A1 (en) | 2011-11-17 | 2014-11-28 | Грюненталь Гмбх | Resistance to fracture an oral pharmaceutical dosage form comprising a pharmacologically active ingredient opioid antagonist and / or a means, is disgusting, polyalkylene oxide and anionic polymers |
EP2782558A4 (en) * | 2011-11-22 | 2015-03-18 | Watson Pharmaceuticals Inc | Immediate release abuse deterrent tablet |
TW201336529A (en) * | 2011-12-09 | 2013-09-16 | Purdue Pharma Lp | Pharmaceutical dosage forms comprising poly( ε -caprolactone) and polyethylene oxide |
EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
MX362357B (en) | 2012-04-18 | 2019-01-14 | Gruenenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form. |
JP6067100B2 (en) | 2012-04-18 | 2017-01-25 | マリンクロッド エルエルシー | Immediate release abuse deterrent pharmaceutical composition |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
CA2877183A1 (en) | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
CA2877774C (en) | 2012-07-12 | 2017-07-18 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
EP3446685A1 (en) | 2012-11-30 | 2019-02-27 | Acura Pharmaceuticals, Inc. | Self-regulated release of active pharmaceutical ingredient |
KR101840526B1 (en) | 2013-02-05 | 2018-03-20 | 퍼듀 퍼머 엘피 | Tamper resistant pharmaceutical formulations |
US9572885B2 (en) | 2013-03-15 | 2017-02-21 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
WO2014146093A2 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
JP6255474B2 (en) | 2013-03-15 | 2017-12-27 | マリンクロッド エルエルシー | Abuse deterrent solid dosage form for immediate release with functional secant |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
AR096439A1 (en) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | DOSAGE METHOD RESISTING TO INDEED USE CONTAINING ONE OR MORE PARTICLES |
JP6445537B2 (en) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant dosage forms containing one or more particles |
EA032465B1 (en) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
NZ719087A (en) | 2013-11-13 | 2017-12-22 | Euro Celtique Sa | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
AU2014356581C1 (en) | 2013-11-26 | 2020-05-28 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10632113B2 (en) | 2014-02-05 | 2020-04-28 | Kashiv Biosciences, Llc | Abuse-resistant drug formulations with built-in overdose protection |
CA2943728C (en) | 2014-03-26 | 2020-03-24 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release biphasic matrix solid dosage form |
AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
CA2949422A1 (en) | 2014-05-26 | 2015-12-03 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
ES2963078T3 (en) | 2014-07-03 | 2024-03-25 | SpecGx LLC | Abuse-deterrent immediate-release formulations comprising non-cellulosic polysaccharides |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
JP5888387B1 (en) * | 2014-10-22 | 2016-03-22 | ミツミ電機株式会社 | Battery protection circuit, battery protection device, and battery pack |
BR112017022856A2 (en) | 2015-04-24 | 2018-07-17 | Gruenenthal Gmbh | tamper-proof fixed dose combination that provides rapid release of two drugs from particles |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US20160310428A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
US20160310486A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
JP2018526414A (en) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Protection against oral overdose with abuse-inhibiting immediate release formulations |
WO2017059374A1 (en) * | 2015-09-30 | 2017-04-06 | Kashiv Pharma Llc | Overdose protection and abuse deterrent immediate release drug formulation |
US9861629B1 (en) | 2015-10-07 | 2018-01-09 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US20180303757A1 (en) * | 2015-10-23 | 2018-10-25 | Kashiv Pharma Llc | Enhanced abuse-deterrent formulations of oxycodone |
WO2017139106A1 (en) | 2016-02-08 | 2017-08-17 | Mallinckrodt Llc | Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties |
JP6323846B2 (en) * | 2016-04-07 | 2018-05-16 | 塩野義製薬株式会社 | Abuse prevention formulation containing opioid |
US20170296476A1 (en) | 2016-04-15 | 2017-10-19 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
US20180028670A1 (en) | 2016-08-01 | 2018-02-01 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polysaccharide |
JP2019524761A (en) | 2016-08-12 | 2019-09-05 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Anti-modification preparation of ephedrine and its derivatives |
DE202016105585U1 (en) * | 2016-10-06 | 2017-01-23 | L.B. Bohle Maschinen + Verfahren Gmbh | Plant for the production of pharmaceutical tablets |
USD857156S1 (en) * | 2016-11-02 | 2019-08-20 | Innovative Water Care, Llc | Chemical tablet for aquatic systems |
EP3554548A4 (en) | 2016-12-19 | 2020-08-19 | The Regents of The University of California | Noncrushable pill formulatiions |
KR102051132B1 (en) * | 2017-03-17 | 2019-12-02 | 주식회사 종근당 | Pharmaceutical composition for controlled release comprising Mirabegron or its salts |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
WO2019003062A1 (en) * | 2017-06-29 | 2019-01-03 | Zenvision Pharma Llp | Tamper-proof dosage form comprising pharmaceutically active agent |
US10376471B2 (en) * | 2017-07-10 | 2019-08-13 | Gel Cap Technologies, LLC | Dual release dosage form capsule and methods, devices and systems for making same |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2019073028A1 (en) | 2017-10-13 | 2019-04-18 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
JP7293209B2 (en) * | 2017-10-20 | 2023-06-19 | パーデュー、ファーマ、リミテッド、パートナーシップ | Pharmaceutical dosage form |
AU2018390826A1 (en) * | 2017-12-20 | 2020-03-12 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
US10624856B2 (en) | 2018-01-31 | 2020-04-21 | Dharma Laboratories LLC | Non-extractable oral solid dosage forms |
TW202002957A (en) | 2018-02-09 | 2020-01-16 | 德商歌林達有限公司 | Tamper resistant formulation of ephedrine and its derivatives comprising a conversion inhibitor |
CA3111353A1 (en) * | 2018-09-06 | 2020-03-12 | Fachhochschule Nordwestschweiz | Controlled drug release formulation |
CA3112030A1 (en) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
WO2020070547A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
EP3860579A1 (en) | 2018-10-05 | 2021-08-11 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
WO2020070706A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
WO2020079699A1 (en) * | 2018-10-16 | 2020-04-23 | M.O Advanced Technologies (Moat) Ltd | Apparatus and method for prediction of tablet defects propensity |
CN111251521B (en) * | 2018-12-03 | 2022-07-22 | 沈欣 | Method for preparing liquid bead pill |
EP3698776A1 (en) | 2019-02-19 | 2020-08-26 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
CA3138100A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
CN110946086B (en) * | 2019-12-04 | 2023-05-12 | 北京猫猫狗狗科技有限公司 | Discharging device and discharging control method |
WO2021137147A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
WO2021137148A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
CN115666621A (en) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | Sustained release drug delivery systems with reduced impurities and related methods |
USD943706S1 (en) * | 2020-06-10 | 2022-02-15 | Emily Florence Johns | Shower steamer |
Family Cites Families (297)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1485673A (en) * | 1924-03-04 | Ministrator | ||
US1468805A (en) | 1923-09-25 | Htabtin ereund | ||
US1479293A (en) | 1924-01-01 | Hiabtor fbettlid | ||
US636438A (en) | 1899-02-08 | 1899-11-07 | Charles H Lovejoy | Molder's chaplet. |
US2654756A (en) | 1949-10-20 | 1953-10-06 | Mallinckrodt Chemical Works | Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone |
US2772270A (en) | 1954-10-21 | 1956-11-27 | M J Lewenstein | 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone |
US3096248A (en) | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
US3097144A (en) | 1960-10-14 | 1963-07-09 | Upjohn Co | Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol |
US3806603A (en) * | 1969-10-13 | 1974-04-23 | W Gaunt | Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm |
US3885027A (en) | 1971-04-12 | 1975-05-20 | West Laboratories Inc | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
US3966747A (en) * | 1972-10-26 | 1976-06-29 | Bristol-Myers Company | 9-Hydroxy-6,7-benzomorphans |
US3888027A (en) | 1973-07-30 | 1975-06-10 | Kennametal Inc | Arrangement for enhancing blade life |
US3980766A (en) | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
US3941865A (en) * | 1973-12-10 | 1976-03-02 | Union Carbide Corporation | Extrusion of ethylene oxide resins |
DE2530563C2 (en) * | 1975-07-09 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Analgesic drugs with reduced potential for abuse |
GB1598458A (en) | 1977-04-01 | 1981-09-23 | Hoechst Uk Ltd | Tableting of microcapsules |
US4175119A (en) | 1978-01-11 | 1979-11-20 | Porter Garry L | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs |
US4211681A (en) | 1978-08-16 | 1980-07-08 | Union Carbide Corporation | Poly(ethylene oxide) compositions |
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
DE3002664C2 (en) | 1980-01-25 | 1989-05-18 | Titmus Eurocon Kontaktlinsen Gmbh & Co Kg, 8750 Aschaffenburg | Soft contact lens |
IL70071A (en) | 1982-11-01 | 1987-12-31 | Merrell Dow Pharma | Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient |
US4501828A (en) * | 1983-01-20 | 1985-02-26 | General Technology Applications,Inc. | Dissolving water soluble polymers |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
FR2557459B1 (en) | 1984-01-02 | 1986-05-30 | Lhd Lab Hygiene Dietetique | POLYCAPROLACTONE-BASED INERT MATRIX FOR ORAL ADMINISTRATION OF A MEDICAMENT, AND METHOD FOR PREPARING THE GALENIC FORM COMPRISING THE SAME |
US4599342A (en) | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US4629621A (en) | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
AU592065B2 (en) | 1984-10-09 | 1990-01-04 | Dow Chemical Company, The | Sustained release dosage form based on highly plasticized cellulose ether gels |
GB8507779D0 (en) | 1985-03-26 | 1985-05-01 | Fujisawa Pharmaceutical Co | Drug carrier |
US4616644A (en) | 1985-06-14 | 1986-10-14 | Johnson & Johnson Products, Inc. | Hemostatic adhesive bandage |
AU583639B2 (en) | 1985-06-24 | 1989-05-04 | Pitman-Moore Australia Limited | Ingestible capsules |
US4619988A (en) | 1985-06-26 | 1986-10-28 | Allied Corporation | High strength and high tensile modulus fibers or poly(ethylene oxide) |
EP0328775B1 (en) | 1985-06-28 | 1993-10-20 | Carrington Laboratories, Inc. | Processes for preparation of aloe products, products produced thereby and compositions thereof |
US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
DE3689650T2 (en) | 1985-12-17 | 1994-05-26 | United States Surgical Corp | High molecular weight bioabsorbable polymers and implants thereof. |
US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US4713243A (en) | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
USRE33093E (en) | 1986-06-16 | 1989-10-17 | Johnson & Johnson Consumer Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
EP0277289B8 (en) | 1986-11-10 | 2003-05-21 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
US4892778A (en) * | 1987-05-27 | 1990-01-09 | Alza Corporation | Juxtaposed laminated arrangement |
US5019397A (en) * | 1988-04-21 | 1991-05-28 | Alza Corporation | Aqueous emulsion for pharmaceutical dosage form |
US5160743A (en) | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US4960814A (en) | 1988-06-13 | 1990-10-02 | Eastman Kodak Company | Water-dispersible polymeric compositions |
US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
US5139790A (en) * | 1988-10-14 | 1992-08-18 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
US5004601A (en) * | 1988-10-14 | 1991-04-02 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5330766A (en) | 1989-01-06 | 1994-07-19 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5051222A (en) | 1989-09-01 | 1991-09-24 | Air Products And Chemicals, Inc. | Method for making extrudable polyvinyl alcohol compositions |
EP0418596A3 (en) | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
US5200197A (en) * | 1989-11-16 | 1993-04-06 | Alza Corporation | Contraceptive pill |
GB8926612D0 (en) | 1989-11-24 | 1990-01-17 | Erba Farmitalia | Pharmaceutical compositions |
FR2664851B1 (en) * | 1990-07-20 | 1992-10-16 | Oreal | METHOD OF COMPACTING A POWDER MIXTURE FOR OBTAINING A COMPACT ABSORBENT OR PARTIALLY DELITABLE PRODUCT AND PRODUCT OBTAINED BY THIS PROCESS. |
SE9003904D0 (en) | 1990-12-07 | 1990-12-07 | Astra Ab | METHOD FOR THE MANUFACTURE OF A PHARMACEUTICAL DOSAGE FORM |
US5273758A (en) * | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
WO1993006723A1 (en) | 1991-10-04 | 1993-04-15 | Olin Corporation | Fungicide tablet |
US5405366A (en) * | 1991-11-12 | 1995-04-11 | Nepera, Inc. | Adhesive hydrogels having extended use lives and process for the preparation of same |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
ATE140620T1 (en) | 1991-12-05 | 1996-08-15 | Mallinckrodt Veterinary Inc | GLASSY CARBOHYDRATE MATRICE FOR ADMINISTRATION OF DELAYED RELEASE MEDICATIONS |
EP0617612B1 (en) | 1991-12-18 | 1997-09-10 | Warner-Lambert Company | A process for the preparation of a solid dispersion |
US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
DE69216642T2 (en) | 1992-01-13 | 1997-05-07 | Pfizer | METHOD FOR PRODUCING TABLETS WITH HIGH STRENGTH |
US5393528A (en) * | 1992-05-07 | 1995-02-28 | Staab; Robert J. | Dissolvable device for contraception or delivery of medication |
US5324351A (en) | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
DE4227385A1 (en) | 1992-08-19 | 1994-02-24 | Kali Chemie Pharma Gmbh | Pancreatin micropellets |
AU682827B2 (en) * | 1992-09-18 | 1997-10-23 | Astellas Pharma Inc. | Sustained-release hydrogel preparation |
FI101039B (en) | 1992-10-09 | 1998-04-15 | Eeva Kristoffersson | Method for preparing medicated pellets |
AU679937B2 (en) | 1992-11-18 | 1997-07-17 | Johnson & Johnson Consumer Products, Inc. | Extrudable compositions for topical or transdermal drug delivery |
FR2701152B1 (en) | 1993-02-03 | 1995-03-10 | Digipress Sa | Method for manufacturing a master disc for producing a pressing die, in particular optical discs, pressing die obtained by this process and optical disc obtained from this pressing die. |
DE4309528C2 (en) | 1993-03-24 | 1998-05-20 | Doxa Gmbh | Casein film or film tube, process for their production and their use |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
EP0647448A1 (en) | 1993-10-07 | 1995-04-12 | Euroceltique S.A. | Orally administrable opioid formulations having extended duration of effect |
US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
KR100354702B1 (en) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | Manufacturing method and sustained release composition of pharmaceutical composition |
ES2168290T3 (en) | 1993-11-23 | 2002-06-16 | Euro Celtique Sa | METHOD FOR PREPARING A SUSTAINED RELEASE COMPOSITION. |
GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
WO1995022318A1 (en) | 1994-02-17 | 1995-08-24 | Pankaj Modi | Drugs, vaccines and hormones in polylactide coated microspheres |
CA2182282C (en) | 1994-02-16 | 2006-04-18 | Jacqueline E. Briskin | Process for preparing fine particle pharmaceutical formulations |
US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
JP2977907B2 (en) | 1994-05-06 | 1999-11-15 | ファイザー・インコーポレーテッド | Controlled release dosage form of azithromycin |
AT403988B (en) | 1994-05-18 | 1998-07-27 | Lannacher Heilmittel | SOLID ORAL RETARDED PREPARATION |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
US5914131A (en) * | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
DE4426245A1 (en) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-phenyl-3-dimethylamino-propane compounds with pharmacological activity |
CA2130410C (en) | 1994-08-18 | 2001-12-04 | Albert John Kerklaan | Retractable expandable jack |
US6491945B1 (en) | 1994-09-16 | 2002-12-10 | Alza Corporation | Hydrocodone therapy |
US5516808A (en) | 1994-10-27 | 1996-05-14 | Sawaya; Assad S. | Topical cellulose pharmaceutical formulation |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
DE4446470A1 (en) * | 1994-12-23 | 1996-06-27 | Basf Ag | Process for the production of dividable tablets |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
US5695781A (en) | 1995-03-01 | 1997-12-09 | Hallmark Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers |
US6348469B1 (en) | 1995-04-14 | 2002-02-19 | Pharma Pass Llc | Solid compositions containing glipizide and polyethylene oxide |
US6117453A (en) | 1995-04-14 | 2000-09-12 | Pharma Pass | Solid compositions containing polyethylene oxide and an active ingredient |
ATE214596T1 (en) | 1995-04-14 | 2002-04-15 | Pharma Pass | SOLID COMPOSITIONS CONTAINING A NON-AMORPHOUS ACTIVE SUBSTANCE AND POLYETHYLENE OXIDE |
US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
US5634702A (en) | 1995-09-27 | 1997-06-03 | Fistonich; Juraj | Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure |
GB9523752D0 (en) * | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
DE19547766A1 (en) | 1995-12-20 | 1997-06-26 | Gruenenthal Gmbh | 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as active pharmaceutical ingredients |
US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
ES2168610T3 (en) | 1996-03-12 | 2002-06-16 | Alza Corp | COMPOSITION AND GALENIC FORM CONTAINING AN OPIOID ANTAGONIST. |
US6461644B1 (en) | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
US20020114838A1 (en) * | 1996-04-05 | 2002-08-22 | Ayer Atul D. | Uniform drug delivery therapy |
US6096339A (en) * | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
DE69723248T2 (en) | 1996-04-10 | 2004-05-27 | Warner-Lambert Co. Llc | COMPOSITIONS FOR SYMPATHOMIMETIC AMINE SALT |
US5886164A (en) * | 1996-04-15 | 1999-03-23 | Zeneca Limited | DNA encoding enzymes related to ethylene biosynthesis and ripening from banana |
US20040024006A1 (en) * | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
GB9611328D0 (en) | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
WO1997045091A2 (en) | 1996-05-31 | 1997-12-04 | Euro-Celtique, S.A. | Sustained release oxycodone formulations with no fed/fast effect |
US5955096A (en) | 1996-06-25 | 1999-09-21 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients |
DE09003265T1 (en) | 1996-06-26 | 2010-04-29 | Board of Regents, The University of Texas System, Austin | Extrudable pharmaceutical hot melt adhesive formulation |
US5730564A (en) | 1996-07-24 | 1998-03-24 | Illinois Tool Works Inc. | Cargo load supporting air bag having inflation indicating means, and method of determining proper inflation for spaced loads |
DE19630236A1 (en) | 1996-07-26 | 1998-01-29 | Wolff Walsrode Ag | Biaxially stretched, biodegradable and compostable sausage casing |
US5869669A (en) | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
BE1010353A5 (en) | 1996-08-14 | 1998-06-02 | Boss Pharmaceuticals Ag | Method for manufacture of pharmaceutical products, device for such a method and pharmaceutical products obtained. |
JP4034357B2 (en) | 1996-11-05 | 2008-01-16 | ノバモント・ソシエタ・ペル・アチオニ | Biodegradable polymer composition comprising starch and thermoplastic polymer |
US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
US5948787A (en) | 1997-02-28 | 1999-09-07 | Alza Corporation | Compositions containing opiate analgesics |
FR2761605B1 (en) | 1997-04-07 | 2001-02-23 | Prographarm Lab | MULTIPARTICULAR PHARMACEUTICAL FORM, ITS CONSTITUENT PARTICLES, METHOD AND PLANT FOR THEIR MANUFACTURE |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
EP0998271B3 (en) * | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
IL121038A0 (en) | 1997-06-09 | 1997-11-20 | Technion Res & Dev Foundation | A pharmaceutical composition for lowering glucose level in blood |
DE19724181A1 (en) | 1997-06-09 | 1998-12-10 | Bayer Ag | Multiple unit retard preparations and process for their preparation |
WO1998056359A2 (en) | 1997-06-13 | 1998-12-17 | Roland Bodmeier | Compounds which delay the release of active substances |
GB9713703D0 (en) | 1997-06-30 | 1997-09-03 | Johnson Matthey Plc | Preparation of opiates |
DK1009387T3 (en) | 1997-07-02 | 2006-08-14 | Euro Celtique Sa | Long-release stabilized tramadol formulations |
AU739974B2 (en) * | 1997-09-26 | 2001-10-25 | Magna Interior Systems Inc. | Fastener assembly for joining two interior panels |
US6066339A (en) | 1997-10-17 | 2000-05-23 | Elan Corporation, Plc | Oral morphine multiparticulate formulation |
DE19749724A1 (en) | 1997-11-11 | 1999-06-10 | Gruenenthal Gmbh | Use of a combination of opioid and alpha-adrenergic agonist in pain relievers |
PT1033975E (en) * | 1997-11-28 | 2002-07-31 | Knoll Ag | PROCESS FOR THE PREPARATION OF BIOLOGICALLY ACTIVE NAO-CRYSTALLINE SUBSTANCES ISSUED OF DISSOLVENTS |
DE19753534A1 (en) | 1997-12-03 | 1999-06-10 | Bayer Ag | Biodegradable thermoplastic polyester-amides with good mechanical properties for molding, film and fiber, useful for e.g. compostable refuse bag |
GB9726365D0 (en) | 1997-12-13 | 1998-02-11 | Ciba Sc Holding Ag | Compounds |
PT1685839E (en) | 1997-12-22 | 2013-07-08 | Euro Celtique Sa | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist |
CA2314896C (en) * | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | A method of preventing abuse of opioid dosage forms |
NZ504834A (en) | 1997-12-22 | 2001-12-21 | Schering Corp | Tricyclic amide molecular dispersion composition with enhanced bioavailability |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
DE19800698A1 (en) | 1998-01-10 | 1999-07-15 | Bayer Ag | Biodegradable polyester amides with block-like polyester and polyamide segments |
US6251430B1 (en) * | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
EP0980894B1 (en) | 1998-03-05 | 2004-06-23 | Mitsui Chemicals, Inc. | Polylactic acid composition and film thereof |
US6245357B1 (en) | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
DE19822979A1 (en) | 1998-05-25 | 1999-12-02 | Kalle Nalo Gmbh & Co Kg | Film with starch or starch derivatives and polyester urethanes and process for their production |
EP0974343B1 (en) | 1998-07-22 | 2004-09-29 | Pharma Pass II LLC | Process for manufacturing a solid metoprolol composition |
US6117452A (en) | 1998-08-12 | 2000-09-12 | Fuisz Technologies Ltd. | Fatty ester combinations |
DE19855440A1 (en) | 1998-12-01 | 2000-06-08 | Basf Ag | Process for the production of solid dosage forms by melt extrusion |
IE981008A1 (en) | 1998-12-02 | 2000-06-14 | Fuisz Internat Ltd | Microparticles Containing Water Insoluble Active Agents |
EP1005863A1 (en) | 1998-12-04 | 2000-06-07 | Synthelabo | Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof |
US6238697B1 (en) * | 1998-12-21 | 2001-05-29 | Pharmalogix, Inc. | Methods and formulations for making bupropion hydrochloride tablets using direct compression |
DE19901683B4 (en) | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Controlled-release analgesic |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
DE19940944B4 (en) * | 1999-08-31 | 2006-10-12 | Grünenthal GmbH | Retarded, oral, pharmaceutical dosage forms |
ATE279186T1 (en) | 1999-08-31 | 2004-10-15 | Gruenenthal Gmbh | SUSTAINED-RELEASE PHARMACEUTICAL FORM CONTAINING TRAMADOL ACCHARINATE |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US6491683B1 (en) | 1999-09-07 | 2002-12-10 | Alza Corporation | Osmotic dosage form composed of an extruded polymer tube form |
US6177567B1 (en) * | 1999-10-15 | 2001-01-23 | Boehringer Ingelheim Chemicals, Inc. | Method for preparing oxycodone |
DE19960494A1 (en) * | 1999-12-15 | 2001-06-21 | Knoll Ag | Device and method for producing solid active substance-containing forms |
WO2001045644A2 (en) | 1999-12-23 | 2001-06-28 | Combe International Ltd. | Dental adhesive device and method for producing same |
ECSP003314A (en) | 2000-01-11 | 2000-03-22 | DELAYED DRUG FORMULATIONS CONTAINING A COMBINATION OF AN OPIOID AND AN - AGONIST | |
US6680070B1 (en) | 2000-01-18 | 2004-01-20 | Albemarle Corporation | Particulate blends and compacted products formed therefrom, and the preparation thereof |
HUP0204163A2 (en) | 2000-02-08 | 2003-04-28 | Euro-Celtique S.A. | Controlled-release composition containing opioid agonist and antagonist and process for its preparation |
US6277409B1 (en) * | 2000-02-11 | 2001-08-21 | Mcneil-Ppc, Inc. | Protective coating for tablet |
DE10015479A1 (en) | 2000-03-29 | 2001-10-11 | Basf Ag | Solid oral dosage forms with delayed release of active ingredient and high mechanical stability |
US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
DE10025947A1 (en) | 2000-05-26 | 2001-11-29 | Gruenenthal Gmbh | Active ingredient combination containing montirelin and a compound with opioid activity |
DE10025948A1 (en) | 2000-05-26 | 2001-11-29 | Gruenenthal Gmbh | drug combination |
EP1285902A4 (en) | 2000-05-29 | 2007-04-18 | Shionogi & Co | Method for labeling with tritium |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
DE10036400A1 (en) | 2000-07-26 | 2002-06-06 | Mitsubishi Polyester Film Gmbh | White, biaxially oriented polyester film |
WO2002026928A1 (en) | 2000-09-28 | 2002-04-04 | The Dow Chemical Company | Polymer composite structures useful for controlled release systems |
AU2738302A (en) * | 2000-10-30 | 2002-05-15 | Euro Celtique Sa | Controlled release hydrocodone formulations |
US20020187192A1 (en) | 2001-04-30 | 2002-12-12 | Yatindra Joshi | Pharmaceutical composition which reduces or eliminates drug abuse potential |
UA81224C2 (en) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
US20030065002A1 (en) * | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
DE60216078T2 (en) * | 2001-05-11 | 2007-07-05 | Endo Pharmaceuticals Inc. | OPIOID CONTAINING ARZNEIFORM AGAINST MISUSE |
US20030064122A1 (en) | 2001-05-23 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse resistant pharmaceutical composition containing capsaicin |
CA2449519A1 (en) | 2001-06-08 | 2002-12-19 | Endo Pharmaceuticals, Inc. | Controlled release dosage forms using acrylic polymer, and process for making the same |
US7968119B2 (en) | 2001-06-26 | 2011-06-28 | Farrell John J | Tamper-proof narcotic delivery system |
PL207748B1 (en) * | 2001-07-06 | 2011-01-31 | Penwest Pharmaceuticals Company | Sustained release formulations of oxymorphone |
CA2456322A1 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique, S.A. | Compositions and methods to prevent abuse of opioids |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US7141250B2 (en) * | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US7157103B2 (en) * | 2001-08-06 | 2007-01-02 | Euro-Celtique S.A. | Pharmaceutical formulation containing irritant |
US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
WO2003015531A2 (en) | 2001-08-06 | 2003-02-27 | Thomas Gruber | Pharmaceutical formulation containing dye |
CA2455420A1 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique, S.A. | Compositions and methods to prevent abuse of opioids |
US20030069318A1 (en) * | 2001-08-21 | 2003-04-10 | Wenbin Dang | Salts of analgesic substances in oil, and methods of making and using the same |
US6691698B2 (en) | 2001-09-14 | 2004-02-17 | Fmc Technologies Inc. | Cooking oven having curved heat exchanger |
US20030068276A1 (en) | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
US20030092724A1 (en) | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
US20040253310A1 (en) * | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
EP1429735A2 (en) | 2001-09-26 | 2004-06-23 | Klaus-Jürgen Steffens | Method and device for producing granulates that comprise at least one pharmaceutical active substance |
JP2005508325A (en) | 2001-09-28 | 2005-03-31 | マクニール−ピーピーシー・インコーポレイテッド | Dosage form having an inner core and an outer shell |
US20030229158A1 (en) | 2001-09-28 | 2003-12-11 | Chen Jen Chi | Polymer composition and dosage forms comprising the same |
US6982094B2 (en) | 2001-09-28 | 2006-01-03 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
PE20030527A1 (en) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20040126428A1 (en) * | 2001-11-02 | 2004-07-01 | Lyn Hughes | Pharmaceutical formulation including a resinate and an aversive agent |
FR2833838B1 (en) | 2001-12-21 | 2005-09-16 | Ellipse Pharmaceuticals | METHOD FOR MANUFACTURING A TABLET INCLUDING A MORPHINIC ANALGESIC AND TABLET OBTAINED |
US20030161882A1 (en) * | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
DK1476138T3 (en) | 2002-02-21 | 2012-02-20 | Valeant Internat Barbados Srl | Modified release formulations of at least one form of tramadol |
GB0204772D0 (en) | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Pharmaceutical dosage forms |
DE10217232B4 (en) * | 2002-04-18 | 2004-08-19 | Ticona Gmbh | Process for the production of filled granules from polyethylene of high or ultra-high molecular weight |
US20050106249A1 (en) * | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
CN1665482A (en) * | 2002-04-29 | 2005-09-07 | 阿尔扎公司 | Methods and dosage forms for controlled delivery of oxycodone |
AU2003234395B2 (en) | 2002-05-13 | 2008-01-24 | Endo Pharmaceuticals Inc. | Abuse-resistant opioid solid dosage form |
WO2003097608A2 (en) * | 2002-05-17 | 2003-11-27 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
WO2003101384A2 (en) | 2002-05-31 | 2003-12-11 | Alza Corporation | Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone |
US7776314B2 (en) * | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10250083A1 (en) | 2002-06-17 | 2003-12-24 | Gruenenthal Gmbh | Dosage form protected against abuse |
CA2491572C (en) * | 2002-07-05 | 2010-03-23 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
US20040011806A1 (en) * | 2002-07-17 | 2004-01-22 | Luciano Packaging Technologies, Inc. | Tablet filler device with star wheel |
JP2005538105A (en) | 2002-07-25 | 2005-12-15 | ファルマシア・コーポレーション | Method for producing a solid dosage form coated with two layers comprising a water-insoluble polymer and a water-soluble pore-forming substance |
CA2495182A1 (en) | 2002-08-15 | 2004-02-26 | Noramco, Inc. | Oxycodone-hydrochloride polymorphs |
EP1539098B1 (en) | 2002-09-20 | 2011-08-10 | Fmc Corporation | Cosmetic composition containing microcrystalline cellulose |
CA2499994C (en) | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
BR0314787A (en) * | 2002-09-28 | 2005-07-26 | Mcneil Ppc Inc | Modified Release Dosage Form |
DE10250088A1 (en) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
DE10250084A1 (en) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
DE10250087A1 (en) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Dosage form protected against abuse |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
US20040110781A1 (en) | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
CA2519556C (en) | 2003-04-21 | 2011-01-18 | Benjamin Oshlack | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same |
CL2004000927A1 (en) | 2003-04-30 | 2005-01-28 | Purdue Pharma Lp | TRANSDERMAL DOSAGE FORM THAT INCLUDES AN ACTIVE AGENT, A NEXT SURFACE AND A DISTAL SURFACE. |
US20060251724A1 (en) | 2003-05-06 | 2006-11-09 | Farrell Thomas P | Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutical dosage forms and methods of preparing the same |
US20040241234A1 (en) | 2003-06-02 | 2004-12-02 | Alpharma, Inc. | Controlled release press-coated formulations of water-soluble active agents |
US6864370B1 (en) * | 2003-06-05 | 2005-03-08 | Zhaiwei Lin | Process for manufacturing oxycodone |
TWI357815B (en) | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
US20050031655A1 (en) | 2003-08-04 | 2005-02-10 | Schering Plough Healthcare Products, Inc. | Emulsion composition |
DE102004020220A1 (en) | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
CA2534925A1 (en) * | 2003-08-06 | 2005-02-24 | Gruenenthal Gmbh | Dosage form that is safeguarded from abuse |
DE10361596A1 (en) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102004032051A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
US20070048228A1 (en) * | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
US20050089570A1 (en) * | 2003-09-26 | 2005-04-28 | Evangeline Cruz | Oros push-stick for controlled delivery of active agents |
CA2541371C (en) | 2003-10-03 | 2014-12-16 | Atul M. Mehta | Extended release formulations of opioids and method of use thereof |
EP1677798A2 (en) | 2003-10-29 | 2006-07-12 | Alza Corporation | Once-a-day, oral, controlled-release, oxycodone dosage forms |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
WO2005070760A1 (en) | 2004-01-23 | 2005-08-04 | Antoine Sakellarides | Shock absorbing system for rowing boat oarlock |
WO2005079752A2 (en) | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
TW201509943A (en) * | 2004-03-30 | 2015-03-16 | Euro Celtique Sa | Oxycodone hydrochloride composition, pharmaceutical dosage form, sustained release oral dosage form and pharmaceutically acceptable package having less than 25 PPM 14-hydroxycodeinone |
WO2005102286A1 (en) * | 2004-04-22 | 2005-11-03 | Grünenthal GmbH | Method for the production of an abuse-proof, solid form of administration |
JP2006002886A (en) * | 2004-06-18 | 2006-01-05 | Noriatsu Kojima | Drain pipe |
JP2006002884A (en) * | 2004-06-18 | 2006-01-05 | Mitsubishi Plastics Ind Ltd | Connector |
WO2006002286A1 (en) * | 2004-06-22 | 2006-01-05 | Magna International Inc. | Sealing molding for a motor vehicle |
PL1765303T5 (en) | 2004-07-01 | 2023-05-22 | Grünenthal GmbH | Oral dosage form safeguarded against abuse |
AR049839A1 (en) | 2004-07-01 | 2006-09-06 | Gruenenthal Gmbh | PROCEDURE FOR THE PRODUCTION OF A SOLID PHARMACEUTICAL FORM, PROTECTED AGAINST ABUSE |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
AR053304A1 (en) | 2004-07-01 | 2007-05-02 | Gruenenthal Gmbh | PROTECTED ORAL PHARMACEUTICAL FORMS AGAINST ABUSE WITH CONTROLLED RELEASE OF (1R, 2R) -3- (3 DIMETHYLAMIN-1-ETIL-2METIL-PROPIL) PHENOL AND PROCEDURE FOR PRODUCTION. |
GB0421149D0 (en) | 2004-09-23 | 2004-10-27 | Johnson Matthey Plc | Preparation of oxycodone |
MX2007009162A (en) | 2005-01-28 | 2007-10-23 | Euro Celtique Sa | Alcohol resistant dosage forms. |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
US20080274183A1 (en) | 2005-02-04 | 2008-11-06 | Phillip Michael Cook | Thermoplastic articles containing a medicament |
US7732427B2 (en) | 2005-03-31 | 2010-06-08 | University Of Delaware | Multifunctional and biologically active matrices from multicomponent polymeric solutions |
BRPI0612802A2 (en) * | 2005-07-07 | 2010-11-30 | Farnam Co Inc | sustained release pharmaceutical compositions for extremely water soluble drugs |
US20070092573A1 (en) | 2005-10-24 | 2007-04-26 | Laxminarayan Joshi | Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist |
PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
US20070117826A1 (en) * | 2005-11-23 | 2007-05-24 | Forest Laboratories, Inc. | Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone |
US20090022798A1 (en) | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
US20070212414A1 (en) | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
US7778314B2 (en) | 2006-05-04 | 2010-08-17 | Texas Instruments Incorporated | Apparatus for and method of far-end crosstalk (FEXT) detection and estimation |
SA07280459B1 (en) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
EP2121699B1 (en) | 2006-12-04 | 2012-09-19 | Noramco, Inc. | Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone |
PE20081632A1 (en) | 2007-01-12 | 2008-12-10 | Wyeth Corp | TABLET TO TABLET COMPOSITIONS |
EP2104493A2 (en) | 2007-01-16 | 2009-09-30 | Egalet A/S | Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
GB2450691A (en) | 2007-07-02 | 2009-01-07 | Alpharma Aps | One-pot preparation of oxycodone from thebaine |
EP2262484B1 (en) | 2008-03-11 | 2013-01-23 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8671872B2 (en) | 2009-02-16 | 2014-03-18 | Thomas Engineering Inc. | Production coater with exchangeable drums |
KR101738369B1 (en) * | 2009-07-22 | 2017-05-22 | 그뤼넨탈 게엠베하 | Hot-melt extruded controlled release dosage form |
US9492492B2 (en) * | 2010-12-17 | 2016-11-15 | Johnson & Johnson Consumer Inc. | Compositions comprising Lilium martagon extracts and uses thereof |
EP2826468A1 (en) * | 2010-12-22 | 2015-01-21 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
US9846413B2 (en) * | 2011-09-08 | 2017-12-19 | Fire Avert, Llc. | Safety shut-off device and method of use |
US10764498B2 (en) * | 2017-03-22 | 2020-09-01 | Canon Kabushiki Kaisha | Image processing apparatus, method of controlling the same, and storage medium |
US10764499B2 (en) * | 2017-06-16 | 2020-09-01 | Microsoft Technology Licensing, Llc | Motion blur detection |
-
2007
- 2007-08-22 SA SA7280459A patent/SA07280459B1/en unknown
- 2007-08-23 JO JO2007345A patent/JO2858B1/en active
- 2007-08-24 PT PT10192644T patent/PT2292230E/en unknown
- 2007-08-24 PT PT111569976T patent/PT2343071E/en unknown
- 2007-08-24 DE DE602007002596T patent/DE602007002596D1/en active Active
- 2007-08-24 KR KR1020177029318A patent/KR20170118249A/en not_active Application Discontinuation
- 2007-08-24 ES ES11157006T patent/ES2417334T3/en active Active
- 2007-08-24 PL PL09156843T patent/PL2082742T3/en unknown
- 2007-08-24 SI SI200731010T patent/SI2311459T1/en unknown
- 2007-08-24 ES ES10192627T patent/ES2390419T3/en active Active
- 2007-08-24 ES ES11156997T patent/ES2411695T3/en active Active
- 2007-08-24 ME MEP-2011-27A patent/ME01339B/en unknown
- 2007-08-24 ES ES10192644T patent/ES2388615T3/en active Active
- 2007-08-24 ME MEP-2009-348A patent/ME01064B/en unknown
- 2007-08-24 SI SI200731241T patent/SI2399580T1/en unknown
- 2007-08-24 EP EP09156832A patent/EP2070538B1/en active Active
- 2007-08-24 ES ES10192641T patent/ES2388591T3/en active Active
- 2007-08-24 DE DE602007010974T patent/DE602007010974D1/en active Active
- 2007-08-24 SI SI200731243T patent/SI2343071T1/en unknown
- 2007-08-24 AT AT09156832T patent/ATE489953T1/en active
- 2007-08-24 CN CN2012101965722A patent/CN102688213A/en active Pending
- 2007-08-24 PT PT111570131T patent/PT2399580E/en unknown
- 2007-08-24 DK DK09156838.6T patent/DK2080514T3/en active
- 2007-08-24 CN CN201710126802.0A patent/CN107412179B/en active Active
- 2007-08-24 AR ARP070103759A patent/AR062511A1/en not_active Application Discontinuation
- 2007-08-24 ES ES07114982T patent/ES2334466T3/en active Active
- 2007-08-24 PE PE2015000012A patent/PE20150340A1/en active IP Right Grant
- 2007-08-24 PT PT111570065T patent/PT2399579E/en unknown
- 2007-08-24 PL PL11156997T patent/PL2343071T3/en unknown
- 2007-08-24 SI SI200730513T patent/SI2070538T1/en unknown
- 2007-08-24 SI SI200730120T patent/SI1897545T1/en unknown
- 2007-08-24 RS RS20130244A patent/RS52798B/en unknown
- 2007-08-24 NZ NZ574447A patent/NZ574447A/en unknown
- 2007-08-24 DK DK10192641.8T patent/DK2292229T3/en active
- 2007-08-24 PL PL09156838T patent/PL2080514T3/en unknown
- 2007-08-24 EP EP11156997A patent/EP2343071B1/en active Active
- 2007-08-24 CN CN201210135209.XA patent/CN102657630B/en not_active Ceased
- 2007-08-24 DK DK11156997.6T patent/DK2343071T3/en active
- 2007-08-24 SI SI200730982T patent/SI2292229T1/en unknown
- 2007-08-24 EP EP11157013A patent/EP2399580B1/en active Active
- 2007-08-24 DK DK11157013.1T patent/DK2399580T3/en active
- 2007-08-24 PL PL09156832T patent/PL2070538T3/en unknown
- 2007-08-24 PL PL11157006T patent/PL2399579T3/en unknown
- 2007-08-24 KR KR1020147008575A patent/KR101568100B1/en active IP Right Grant
- 2007-08-24 AP AP2009004770A patent/AP2009004770A0/en unknown
- 2007-08-24 WO PCT/IB2007/002515 patent/WO2008023261A1/en active Application Filing
- 2007-08-24 SI SI200731242T patent/SI2399579T1/en unknown
- 2007-08-24 EP EP09156838A patent/EP2080514B1/en active Active
- 2007-08-24 ME MEP-2013-58A patent/ME01550B/en unknown
- 2007-08-24 CN CN201510599504.4A patent/CN105213345B/en active Active
- 2007-08-24 RS RS20110058A patent/RS51591B/en unknown
- 2007-08-24 UA UAA201107825A patent/UA104745C2/en unknown
- 2007-08-24 JP JP2009525126A patent/JP5069300B2/en active Active
- 2007-08-24 RS RS20130223A patent/RS52793B/en unknown
- 2007-08-24 PE PE2007001153A patent/PE20080765A1/en active IP Right Grant
- 2007-08-24 DK DK09156832.9T patent/DK2070538T3/en active
- 2007-08-24 RS RS20110171A patent/RS51664B/en unknown
- 2007-08-24 AU AU2007287341A patent/AU2007287341B2/en active Active
- 2007-08-24 PE PE2009000362A patent/PE20091184A1/en active IP Right Grant
- 2007-08-24 PT PT07114982T patent/PT1897545E/en unknown
- 2007-08-24 DK DK07114982.7T patent/DK1897545T3/en active
- 2007-08-24 ME MEP-2012-105A patent/ME01482B/en unknown
- 2007-08-24 KR KR1020127021463A patent/KR101455914B1/en active IP Right Grant
- 2007-08-24 BR BRPI0714539A patent/BRPI0714539B8/en active IP Right Grant
- 2007-08-24 CA CA2661573A patent/CA2661573C/en active Active
- 2007-08-24 EA EA201171403A patent/EA023807B1/en not_active IP Right Cessation
- 2007-08-24 PL PL10192641T patent/PL2292229T3/en unknown
- 2007-08-24 KR KR1020167022072A patent/KR101787605B1/en active IP Right Grant
- 2007-08-24 DK DK10192644.2T patent/DK2292230T3/en active
- 2007-08-24 ME MEP-2011-26A patent/ME01255B/en unknown
- 2007-08-24 EP EP07114982A patent/EP1897545B1/en active Active
- 2007-08-24 MX MX2013014243A patent/MX360849B/en unknown
- 2007-08-24 DE DE602007012747T patent/DE602007012747D1/en active Active
- 2007-08-24 ES ES11157013T patent/ES2417335T3/en active Active
- 2007-08-24 MY MYPI2012004970A patent/MY161079A/en unknown
- 2007-08-24 PL PL11157003T patent/PL2384754T3/en unknown
- 2007-08-24 RS RSP-2009/0536A patent/RS51162B/en unknown
- 2007-08-24 PT PT10192641T patent/PT2292229E/en unknown
- 2007-08-24 CL CL2007002485A patent/CL2007002485A1/en unknown
- 2007-08-24 RS RS20120328A patent/RS52402B/en unknown
- 2007-08-24 CN CN201510599477.0A patent/CN105267170B/en not_active Ceased
- 2007-08-24 ES ES11157003T patent/ES2411696T3/en active Active
- 2007-08-24 PE PE2019000935A patent/PE20191048A1/en unknown
- 2007-08-24 PL PL07114982T patent/PL1897545T3/en unknown
- 2007-08-24 KR KR1020157017047A patent/KR101649838B1/en active Application Filing
- 2007-08-24 RS RS20120394A patent/RS52463B/en unknown
- 2007-08-24 DE DE202007011825U patent/DE202007011825U1/en not_active Expired - Lifetime
- 2007-08-24 ES ES09156843T patent/ES2358066T3/en active Active
- 2007-08-24 BR BR122016004010A patent/BR122016004010B8/en active IP Right Grant
- 2007-08-24 ME MEP-2013-67A patent/ME01580B/en unknown
- 2007-08-24 RS RS20130200A patent/RS52779B/en unknown
- 2007-08-24 CN CN201210196662.1A patent/CN102743355B/en active Active
- 2007-08-24 CN CN200780031610.6A patent/CN101583360B/en active Active
- 2007-08-24 MY MYPI20090749A patent/MY146650A/en unknown
- 2007-08-24 TW TW096131511A patent/TWI341213B/en active
- 2007-08-24 EA EA200900343A patent/EA018311B1/en not_active IP Right Cessation
- 2007-08-24 DK DK11157006.5T patent/DK2399579T3/en active
- 2007-08-24 PL PL11157013T patent/PL2399580T3/en unknown
- 2007-08-24 PL PL10192627T patent/PL2311459T3/en unknown
- 2007-08-24 PT PT09156843T patent/PT2082742E/en unknown
- 2007-08-24 PT PT111570032T patent/PT2384754E/en unknown
- 2007-08-24 EP EP10192644A patent/EP2292230B1/en active Active
- 2007-08-24 NZ NZ597760A patent/NZ597760A/en unknown
- 2007-08-24 ES ES09156838T patent/ES2361721T3/en active Active
- 2007-08-24 ME MEP-2011-79A patent/ME01187B/en unknown
- 2007-08-24 DE DE602007010963T patent/DE602007010963D1/en active Active
- 2007-08-24 PT PT09156832T patent/PT2070538E/en unknown
- 2007-08-24 EP EP10192641A patent/EP2292229B1/en active Active
- 2007-08-24 DK DK09156843.6T patent/DK2082742T3/en active
- 2007-08-24 CA CA2707204A patent/CA2707204C/en active Active
- 2007-08-24 SI SI200730563T patent/SI2080514T1/en unknown
- 2007-08-24 AT AT09156838T patent/ATE499101T1/en active
- 2007-08-24 AT AT07114982T patent/ATE444070T1/en active
- 2007-08-24 RS RS20110056A patent/RS51678B/en unknown
- 2007-08-24 RS RS20130265A patent/RS52813B/en unknown
- 2007-08-24 IN IN1813DEN2015 patent/IN2015DN01813A/en unknown
- 2007-08-24 EP EP11157003A patent/EP2384754B1/en active Active
- 2007-08-24 MX MX2009002023A patent/MX2009002023A/en active IP Right Grant
- 2007-08-24 EA EA201300465A patent/EA031873B1/en not_active IP Right Cessation
- 2007-08-24 PE PE2014000147A patent/PE20140854A1/en active IP Right Grant
- 2007-08-24 CN CN201410024630.2A patent/CN103861111B/en active Active
- 2007-08-24 EP EP10192627A patent/EP2311459B1/en active Active
- 2007-08-24 KR KR1020097006064A patent/KR101205579B1/en active IP Right Grant
- 2007-08-24 KR KR1020117024787A patent/KR101496510B1/en active IP Right Grant
- 2007-08-24 ES ES09156832T patent/ES2357376T3/en active Active
- 2007-08-24 NZ NZ608651A patent/NZ608651A/en unknown
- 2007-08-24 MY MYPI20124957 patent/MY153092A/en unknown
- 2007-08-24 DK DK11157003.2T patent/DK2384754T3/en active
- 2007-08-24 EP EP11157006.5A patent/EP2399579B9/en active Active
- 2007-08-24 SI SI200730989T patent/SI2292230T1/en unknown
- 2007-08-24 US US11/844,872 patent/US8894987B2/en active Active
- 2007-08-24 DK DK10192627.7T patent/DK2311459T3/en active
- 2007-08-24 RS RS20120320A patent/RS52401B/en unknown
- 2007-08-24 KR KR1020127021462A patent/KR101514388B1/en active IP Right Grant
- 2007-08-24 PT PT10192627T patent/PT2311459E/en unknown
- 2007-08-24 UA UAA200902798A patent/UA96306C2/en unknown
- 2007-08-24 EP EP09156843A patent/EP2082742B1/en active Active
- 2007-08-24 AT AT09156843T patent/ATE489954T1/en active
- 2007-08-24 PT PT09156838T patent/PT2080514E/en unknown
- 2007-08-24 PL PL10192644T patent/PL2292230T3/en unknown
- 2007-08-24 SI SI200730512T patent/SI2082742T1/en unknown
- 2007-08-24 SI SI200731244T patent/SI2384754T1/en unknown
- 2007-08-24 CN CN201210196551.0A patent/CN102688241B/en active Active
-
2008
- 2008-09-03 HK HK09111397.7A patent/HK1133192A1/en unknown
- 2008-09-03 HK HK09112030.8A patent/HK1132189A1/en unknown
- 2008-09-03 HK HK08109790.5A patent/HK1118225A1/en unknown
- 2008-09-03 HK HK09112034.4A patent/HK1138498A1/en unknown
-
2009
- 2009-02-02 ZA ZA200900755A patent/ZA200900755B/en unknown
- 2009-02-05 GT GT200900023BA patent/GT200900023BA/en unknown
- 2009-02-05 GT GT200900023A patent/GT200900023A/en unknown
- 2009-02-24 IL IL197214A patent/IL197214A/en active IP Right Grant
- 2009-02-24 DO DO2009000026A patent/DOP2009000026A/en unknown
- 2009-02-25 TN TN2009000059A patent/TN2009000059A1/en unknown
- 2009-03-19 CO CO09028553A patent/CO6160317A2/en unknown
- 2009-03-24 MA MA31733A patent/MA30766B1/en unknown
- 2009-03-25 CR CR10691A patent/CR10691A/en unknown
- 2009-08-14 AT AT0050909U patent/AT11571U1/en not_active IP Right Cessation
- 2009-12-11 CY CY20091101293T patent/CY1110573T1/en unknown
- 2009-12-28 HR HR20090688T patent/HRP20090688T1/en unknown
-
2011
- 2011-02-23 CY CY20111100220T patent/CY1111897T1/en unknown
- 2011-02-23 HR HR20110130T patent/HRP20110130T1/en unknown
- 2011-02-23 CY CY20111100217T patent/CY1111887T1/en unknown
- 2011-02-28 HR HR20110147T patent/HRP20110147T1/en unknown
- 2011-05-17 CY CY20111100472T patent/CY1111896T1/en unknown
- 2011-05-20 HR HR20110375T patent/HRP20110375T1/en unknown
- 2011-08-05 DO DO2011000255A patent/DOP2011000255A/en unknown
- 2011-08-16 HK HK11108648.6A patent/HK1154491A1/en unknown
- 2011-08-26 HK HK11109019.5A patent/HK1154788A1/en unknown
- 2011-08-26 HK HK11109020.2A patent/HK1154789A1/en unknown
- 2011-10-18 HK HK12106233.0A patent/HK1165317A1/en unknown
- 2011-10-18 HK HK11111131.4A patent/HK1156845A1/en unknown
- 2011-10-18 HK HK12106234.9A patent/HK1165318A1/en unknown
- 2011-10-18 HK HK12106232.1A patent/HK1165316A1/en unknown
-
2012
- 2012-01-26 IL IL217788A patent/IL217788A0/en active IP Right Grant
- 2012-01-26 IL IL217787A patent/IL217787A0/en active IP Right Grant
- 2012-01-26 IL IL217792A patent/IL217792A/en active IP Right Grant
- 2012-01-26 IL IL217794A patent/IL217794A/en active IP Right Grant
- 2012-01-26 IL IL217790A patent/IL217790A0/en active IP Right Grant
- 2012-01-26 IL IL217791A patent/IL217791A/en active IP Right Grant
- 2012-01-26 IL IL217789A patent/IL217789A0/en active IP Right Grant
- 2012-03-01 JP JP2012045261A patent/JP5373133B2/en active Active
- 2012-04-19 JP JP2012096011A patent/JP2012167102A/en not_active Withdrawn
- 2012-07-13 JP JP2012157159A patent/JP2012229250A/en not_active Withdrawn
- 2012-07-13 JP JP2012157158A patent/JP2012229249A/en not_active Withdrawn
- 2012-07-13 JP JP2012157157A patent/JP5642736B2/en active Active
- 2012-07-25 HR HRP20120613TT patent/HRP20120613T1/en unknown
- 2012-08-07 HR HRP20120641TT patent/HRP20120641T1/en unknown
- 2012-08-20 HR HRP20120670TT patent/HRP20120670T1/en unknown
- 2012-08-22 CY CY20121100749T patent/CY1113220T1/en unknown
- 2012-08-22 CY CY20121100750T patent/CY1113231T1/en unknown
- 2012-09-25 CY CY20121100874T patent/CY1113141T1/en unknown
-
2013
- 2013-03-14 US US13/803,132 patent/US20140030327A1/en not_active Abandoned
- 2013-05-17 HR HRP20130433TT patent/HRP20130433T1/en unknown
- 2013-05-17 HR HRP20130434TT patent/HRP20130434T1/en unknown
- 2013-05-22 HR HRP20130444TT patent/HRP20130444T1/en unknown
- 2013-05-23 US US13/901,199 patent/US20130251801A1/en not_active Abandoned
- 2013-05-23 US US13/901,078 patent/US8815289B2/en active Active
- 2013-05-23 US US13/901,047 patent/US8846086B2/en active Active
- 2013-05-23 US US13/900,873 patent/US8821929B2/en active Active
- 2013-05-23 US US13/901,218 patent/US8911719B2/en active Active
- 2013-05-23 US US13/901,142 patent/US20130251800A1/en not_active Abandoned
- 2013-05-23 US US13/901,174 patent/US20130251797A1/en not_active Abandoned
- 2013-05-23 US US13/901,027 patent/US20130251796A1/en not_active Abandoned
- 2013-05-23 US US13/901,122 patent/US8834925B2/en active Active
- 2013-05-23 US US13/900,963 patent/US8894988B2/en active Active
- 2013-05-23 US US13/900,933 patent/US20130259938A1/en not_active Abandoned
- 2013-06-13 HR HRP20130539TT patent/HRP20130539T1/en unknown
- 2013-09-26 US US14/038,209 patent/US20140024669A1/en not_active Abandoned
- 2013-09-27 US US14/040,535 patent/US8808741B2/en active Active
-
2014
- 2014-04-22 CL CL2014001029A patent/CL2014001029A1/en unknown
- 2014-07-16 CR CR20140340A patent/CR20140340A/en unknown
- 2014-10-16 US US14/515,924 patent/US9084816B2/en active Active
- 2014-10-16 US US14/515,921 patent/US9095615B2/en active Active
- 2014-10-16 US US14/515,857 patent/US9101661B2/en active Active
- 2014-10-16 US US14/515,855 patent/US9095614B2/en active Active
- 2014-10-23 JO JOP/2014/0306A patent/JO3323B1/en active
- 2014-10-29 JP JP2014220816A patent/JP5980881B2/en active Active
-
2015
- 2015-06-03 US US14/729,660 patent/US9492393B2/en active Active
- 2015-06-03 US US14/729,565 patent/US9492389B2/en active Active
- 2015-06-03 US US14/729,634 patent/US9492392B2/en active Active
- 2015-06-03 US US14/729,601 patent/US9492390B2/en active Active
- 2015-06-03 US US14/729,593 patent/US9486412B2/en active Active
- 2015-06-03 US US14/729,626 patent/US9492391B2/en active Active
- 2015-06-03 US US14/729,675 patent/US9486413B2/en active Active
- 2015-06-03 US US14/729,688 patent/US9545380B2/en active Active
- 2015-09-03 IL IL241121A patent/IL241121A/en active IP Right Grant
- 2015-09-03 IL IL241122A patent/IL241122B/en active IP Right Grant
-
2016
- 2016-01-21 AR ARP160100147A patent/AR103463A2/en not_active Application Discontinuation
- 2016-07-27 JP JP2016146843A patent/JP6286491B2/en active Active
- 2016-09-13 US US15/263,932 patent/US9775812B2/en active Active
-
2017
- 2017-01-24 US US15/413,678 patent/US9770416B2/en active Active
- 2017-01-24 US US15/413,656 patent/US9775809B2/en active Active
- 2017-01-24 US US15/413,505 patent/US9763886B2/en active Active
- 2017-01-24 US US15/413,554 patent/US9775811B2/en active Active
- 2017-01-24 US US15/413,635 patent/US9775808B2/en active Active
- 2017-01-24 US US15/413,614 patent/US9763933B2/en active Active
- 2017-01-24 US US15/413,530 patent/US9775810B2/en active Active
- 2017-01-24 US US15/413,580 patent/US9770417B2/en active Active
- 2017-03-20 CL CL2017000669A patent/CL2017000669A1/en unknown
- 2017-05-17 US US15/597,885 patent/US20170246116A1/en not_active Abandoned
- 2017-07-24 US US15/657,643 patent/US20170319491A1/en not_active Abandoned
- 2017-07-24 US US15/657,424 patent/US20170319488A1/en not_active Abandoned
- 2017-07-24 US US15/657,793 patent/US20170319494A1/en not_active Abandoned
- 2017-07-24 US US15/657,895 patent/US20170319497A1/en not_active Abandoned
- 2017-07-24 US US15/657,521 patent/US20170319490A1/en not_active Abandoned
- 2017-07-24 US US15/657,852 patent/US20170319496A1/en not_active Abandoned
- 2017-07-24 US US15/657,916 patent/US20170319498A1/en not_active Abandoned
- 2017-07-24 US US15/657,491 patent/US20170319489A1/en not_active Abandoned
- 2017-07-24 US US15/657,818 patent/US20170319495A1/en not_active Abandoned
- 2017-07-24 US US15/657,599 patent/US20170354607A1/en not_active Abandoned
- 2017-07-24 US US15/657,761 patent/US20170319493A1/en not_active Abandoned
- 2017-07-24 US US15/657,717 patent/US20170319492A1/en not_active Abandoned
- 2017-08-22 US US15/683,472 patent/US20170348241A1/en not_active Abandoned
- 2017-08-22 US US15/683,436 patent/US20170348240A1/en not_active Abandoned
- 2017-10-04 AR ARP170102763A patent/AR109797A2/en not_active Application Discontinuation
- 2017-10-04 AR ARP170102762A patent/AR109796A2/en not_active Application Discontinuation
-
2018
- 2018-01-31 US US15/885,074 patent/US20180369150A1/en not_active Abandoned
- 2018-01-31 US US15/885,254 patent/US10076498B2/en active Active
- 2018-01-31 US US15/885,413 patent/US10076499B2/en active Active
- 2018-05-03 HK HK18105698.4A patent/HK1246175A1/en unknown
- 2018-08-28 US US16/115,024 patent/US20190000767A1/en not_active Abandoned
-
2020
- 2020-07-17 US US16/931,803 patent/US20210169810A1/en not_active Abandoned
- 2020-09-21 US US17/027,088 patent/US11298322B2/en active Active
- 2020-09-21 US US17/027,222 patent/US11304908B2/en active Active
- 2020-09-21 US US17/027,307 patent/US11304909B2/en active Active
-
2022
- 2022-08-22 US US17/892,553 patent/US11904055B2/en active Active
-
2023
- 2023-05-05 US US18/143,927 patent/US11826472B2/en active Active
- 2023-06-05 US US18/205,786 patent/US11938225B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114659554A (en) * | 2022-03-01 | 2022-06-24 | 安徽农业大学 | Fault diagnosis method for biomass granulator |
CN114659554B (en) * | 2022-03-01 | 2023-04-25 | 安徽农业大学 | Fault diagnosis method for biomass granulator |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2661573A1 (en) | Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic | |
CA2913368C (en) | Abuse deterrent immediate release formulation | |
HRP20150835T1 (en) | Controlled release pharmaceutical dosage forms | |
AU2011346758B2 (en) | Tamper resistant solid oral dosage forms | |
AU2005282784B2 (en) | Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax | |
JP2006524249A5 (en) | ||
CA2652981A1 (en) | Robust sustained release formulations | |
CA2640339A1 (en) | Tamper resistant opioid dosage forms | |
HRP20100289T1 (en) | Tamper-resistant products for opioid delivery | |
JP2014510094A5 (en) | ||
JP2010501543A5 (en) | ||
RU2011121010A (en) | PHARMACEUTICAL MEDICINAL FORMS CONTAINING POLY- (Epsilon-caprolactone) | |
KR20090038447A (en) | Multilayer orally disintegrating tablet | |
JP2008528534A5 (en) | ||
EP2768537A2 (en) | Acrylic polymer formulations | |
AU2017241266B2 (en) | Extended release, abuse deterrent dosage forms | |
RU2017112301A (en) | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | |
WO2016120892A1 (en) | Abuse deterrent controlled release solid dosage form | |
HRP20141001T1 (en) | Pharmaceutical spheroids | |
JP7293209B2 (en) | Pharmaceutical dosage form | |
US10624856B2 (en) | Non-extractable oral solid dosage forms | |
JP2021500316A5 (en) | ||
US11439600B2 (en) | Abuse deterrent oral solid dosage form | |
WO2019152002A1 (en) | Non-extractable oral solid dosage forms | |
AU2011202866B2 (en) | Tamper resistant dosage forms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |